document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis operate segmentbiopharmaceutical additional information business segment item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country percentage revenue significant region follow year end december dollar millions united states europe japan china total revenue acquisition divestiture transform bms leadingedge biopharmaceutical company focus exclusively discover develop deliver innovative medicine address unmet medical need transformation encompass area business operation strategy divest diabete nonpharmaceutical business implement acquisition licensing strategy execute productivity transformation initiative pti divestiture include diabete business february mead johnson december convatec august medical imaging january acquisition licensing strategy acquire amylin pharmaceuticals inc amylin august inhibitex inc inhibitex february amira pharmaceuticals inc amira september zymogenetics inc zymogenetics october medarex inc medarex september enter license collaboration arrangement transaction allow continue allow focus resource growth opportunity drive great longterm value disease standpoint focus core therapeutic area oncology virology immunology specialty cardiovascular disease product pharmaceutical product include chemicallysynthesize drug small molecule increase portion product produce biological process typically involve recombinant dna technology call biologics small molecule drug typically administer orally eg form pill tablet drug delivery mechanism biologic typically administer patient injection infusion revenue come product follow therapeutic class virology include human immunodeficiency virus hiv infection oncology neuroscience metabolic immunoscience cardiovascular pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union eu country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition business generic competition follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur eu japan china sell pharmaceutical product country datum provide countrybycountry basis individual country revenue significant outside eu japan china instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present revenue key product estimate basic exclusivity loss eu japan china total revenue product past currently estimate year basic exclusivity loss dollar million eua japan china key product virology baraclude b reyataz c sustiva franchise e oncology erbitux f g sprycel yervoy g g neuroscience abilify h metabolicsm bydureon na j j g byetta na k g g forxigaxigduo na onglyzakombiglyze immunoscience nulojix orencia g g cardiovascular avaproavalide eliquis plavix l note currently estimate early year basic exclusivity loss include statutory extension exclusivity grant instance able obtain additional month exclusivity product base pediatric extension certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity indicate brand name product trademark own wholly own bms specific trademark ownership information include currently market product country region indicate uncertainty china exclusivity law result generic competition china market reference eu include member states european union year end december basic patent application file current member state list product instance date basic exclusivity loss different eu member states eu country basic patent obtain datum protection available b february district court district delaware invalidate composition matter patent covering baraclude entecavir schedule expire include grant pediatric exclusivity appeal pende decision expect face generic competition product begin company prepare legal action event teva pharmaceutical industries ltd teva choose launch generic product prior resolution company appeal c data exclusivity eu expire market exclusivity expire exclusivity period relate sustiva brand include exclusivity relate combination therapy composition matter patent efavirenz expire method use patent treatment hiv infection expire september pediatric exclusivity grant provide additional month period exclusivity add term patent list orange book e exclusivity period relate sustiva efavirenz brand include exclusivity relate combination therapy market exclusivity sustiva expire november countries eu data exclusivity sustiva expire eu f biologic product approve biologics license application bla datum exclusivity expire patent specifically claim composition matter cetuximab active ingredient erbitux right commercialize cetuximab terminate g exclusivity period base regulatory data protection h rights commercialize abilify aripiprazole terminate right commercialize abilify eu terminate june j exclusivity period base formulation patent k exclusivity period base method use patent l datum exclusivity eu expire july major market europe product national patent expired specifically claim bisulfate form clopidogrel generic alternate salt form clopidogrel bisulfate market compete plavix eu february bms sell astrazeneca plc astrazeneca diabetes business bms comprise global alliance include right ownership onglyzakombiglyze forxigaxigduo bydureon byetta symlin summary indication intellectual property position product partner thirdparty manufacturing arrangement product applicable eu japan baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approve food drug administration fda treatment chronic hepatitis b infection baraclude discover develop internally february district court district delaware invalidate composition matter patent covering baraclude schedule expire appeal pende decision expect face generic competition product begin december fda grant pediatric exclusivity baraclude event company successful appeal composition matter patent include pediatric extension expire august company prepare legal action event teva choose launch generic product prior resolution company appeal information patent litigation matter item financial statementsnote legal proceeding contingency composition matter patent expire eu japan uncertainty chinas exclusivity law result generic competition china market entecavir manufacture company party product finish facility reyataz reyataz atazanavir sulfate protease inhibitor treatment human immunodeficiency virus hiv develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net product sale entitle promote reyataz use combination norvir ritonavir non exclusive license agreement abbvie inc abbvie amend royalty pay base percentage net product sale licensing agreement gilead sciences inc gilead develop commercialize fixeddose combination contain atazanavir gilead compound development market exclusivity reyataz expect expire china major eu member country japan data exclusivity eu expire manufacture bulk requirement atazanavir finish product facility sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combine sustiva gilead truvada emtricitabine tenofovir disoproxil fumarate information arrangement gilead strategic alliance item financial statementsnote alliance right market efavirenz canada uk france germany ireland italy spain license merck co inc merck royalty base percentage revenue efavirenz market company japan composition matter patent efavirenz expire method use patent treatment hiv infection expire september additional month period pediatric exclusivity add term patent market exclusivity sustiva expire november countries eu data exclusivity sustiva expire eu certain atripla patent subject patent litigation time patent cover efavirenz composition matter method use challenge obtain bulk requirement efavirenz party produce finished good facility supply party bulk efavirenz gilead responsible produce finished atripla product erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail fda approve erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbase chemotherapy fluorouracil erbitux market north america agreement imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement sign october imclone merck kgaa merck serono japan erbitux receive marketing approval japan july use treat patient advance recurrent colorectal cancer december head neck cancer description alliance imclone strategic alliance item financial statementsnote alliance datum exclusivity erbituxin expire patent specifically claim composition matter cetuximab active molecule erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination fluorouracil antineoplastic agent approve fda combination use claim grant patent expire include grant patent term extension inventorship use patent challenge researcher yeda research development company ltd yeda pursuant settlement agreement execute announce december imclone sanofi yeda end worldwide litigation relate use patent sanofi yeda grant imclone worldwide license use patent datum exclusivity japan expire yeda right license use patent yeda license patent party result product competition erbitux occur unable assess extent competitive impact occur quantify impact yeda grant amgen inc amgen license use patent amgen receive fda approval market egfrproduct compete erbitux obtain finish good requirement cetuximab use north america lilly lilly manufacture bulk requirement cetuximab facility fill finish perform thirdparty bms oversight responsibility description supply agreement lilly manufacture quality assurance sprycel sprycel dasatinib multitargete tyrosine kinase inhibitor approve firstline treatment adult philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate sprycel internally discover strategic alliance otsuka information alliance otsuka strategic alliance item financial statementsnote alliance patent term extension grant extend term basic composition matter patent cover dasatinib june company enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate anda product september early certain circumstance orphan drug exclusivity expired protect product generic application currently approve orphan indication majority eu country composition matter patent cover dasatinib expire april exclude potential term extension composition matter patent expire japan china manufacture bulk requirement dasatinib finish product facility yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable inoperable metastatic melanoma yervoy approve march eu july currently study indication include lung cancer adjuvant melanoma hormonerefractory prostate cancer information research development yervoy research development yervoy discover medarex codevelope company medarex subsidiary patent cover ipilimumab composition matter currently expire eu exclude potential patent term extension datum exclusivity expire eu obtain bulk ipilimumab thirdparty manufacturer finish product facility thirdparty facility abilify abilify aripiprazole atypical antipsychotic agent adult patient schizophrenia bipolar mania disorder major depressive disorder abilify pediatric use schizophrenia bipolar disorder global commercialization agreement otsuka pharmaceutical co ltd otsuka exclude japan china certain asian country information arrangement otsuka strategic alliance item financial statementsnote alliance basic composition matter patent cover aripiprazole term current abilify agreement expire april include grant patent term extension month pediatric extension composition matter patent force major eu country original expiration date extend grant supplementary protection certificate eu country data exclusivity right commercialize eu expire june obtain bulk requirement aripiprazole otsuka company otsuka finish product respective facility bydureon bydureon exenatide extendedrelease injectable suspension onceweekly glucagonlike peptide glp receptor agonist treatment type diabetes bydureon acquire amylin acquisition august bydureon internally discover amylin whollyowne subsidiary company prior sale diabete business february worldwide development commercialization agreement astrazeneca bydureon information arrangement sale diabetes business astrazeneca item financial statementsnote alliance item financial statementsnote asset heldforsale formulation patent expire europe data exclusivity expire japan prior sale diabete business obtain bulk requirement exenatide party microsphere manufacturing process require extend release formulation perform company follow sale diabete business astrazeneca assume manufacturing finishing responsibility byetta byettaexenatide twice daily glp receptor agonist treatment type diabetes byetta acquire amylin acquisition august byetta internally discover amylin whollyowne subsidiary company prior sale diabete business february worldwide development commercialization agreement astrazeneca byetta information arrangement sale diabetes business astrazeneca item financial statement note alliance item financial statementsnote asset heldforsale method use patent expire datum exclusivity expire europe japan prior sale diabete business obtain bulk requirement exenatide party manufacture finishing take place thirdparty facility follow sale diabete business astrazeneca assume manufacturing finishing responsibility forxiga forxiga dapagliflozin oral sodiumglucose cotransporter sglt treatment type diabete mellitus forxiga market farxiga document specifically note refer forxiga farxiga forxiga approve january eu november use adult type diabete mellitus improve glycemic control adjunct diet exercise discussion item management discussion analysis financial condition result operation product pipeline development forxiga internally discover prior sale diabetes business february worldwide development commercialization agreement astrazeneca forxiga information arrangement sale diabetes business astrazeneca item financial statementsnote alliance item financial statementsnote asset heldforsale composition matter patent cover dapagliflozin expire october eu prior sale diabete business manufacture bulk requirement dapagliflozin finish product facility follow sale diabete business bm continue manufacture bulk requirement finish product pursuant supply arrangement agree connection sale diabetes business astrazeneca onglyzakombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicate treatment type diabete adjunct diet exercise kombiglyze saxagliptin metformin hydrochloride extendedrelease approve combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus treatment saxagliptin metformin appropriate komboglyze saxagliptin metformin immediaterelease approve eu combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus inadequately control maximally tolerate dose metformin treat combination saxagliptin metformin separate tablet document specifically note refer kombiglyze komboglyze kombiglyze onglyza internally discover company kombiglyze codevelope company astrazeneca prior sale diabete business february worldwide japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement sale diabetes business astrazeneca arrangement otsuka japan strategic alliance item financial statementsnote alliance item financial statementsnote asset heldforsale composition matter patent cover saxagliptin expire july include grant patent term extension expire eu march eu supplementary protection certificate grant onglyza majority european country expire october supplementary protection certification kombiglyze apply grant france italy spain application pende number european country market exclusivity china expire follow sale diabetes business bm continue manufacture bulk requirement finish product pursuant supply arrangement agree connection sale diabetes business astrazeneca nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity prevention kidney transplant rejection approve launch june approve eu june launch july belatacept internally discover develop patent cover belatacept composition matter expire april eu datum exclusivity expire june eu june manufacture bulk requirement belatacept finish product facility orencia orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderately severely active rheumatoid arthritis inadequate response certain currently available treatment abatacept available intravenous formulation begin subcutaneous formulation orencia discover develop internally approve eu region series patent cover abatacept method use patent term extension grant composition matter patent extend term patent eu composition matter patent covering abatacept expire majority eu country apply supplementary protection certificate pediatric extension supplementary protection certificate protection protection certificate grant datum exclusivity expire eu japan bulk abatacept manufacture company party finish formulation product facility strategic alliance discussion collaboration ono pharmaceutical co ltd ono orencia japan avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi end october bms sanofi announce restructuring alliance follow loss exclusivity plavix avaproavalide major market information alliance sanofi restructuring strategic alliance item financial statementsnote alliance composition matter patent expire march countries eu data exclusivity eu expire august avapro october avalide company sanofi manufacture bulk requirement irbesartan finishing perform sanofi alliance restructuring bmss manufacturing obligation phase sanofi assume company manufacture supply obligation irbesartan product end eliquis eliquis apixaban oral factor xa inhibitor target stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorder apixaban discover internally alliance pfizer inc pfizer information alliance pfizer item financial statementsnote alliance composition matter patent cover apixaban expire february exclude potential patent term extension eu expire apply supplementary protection certificate supplementary protection certificate grant expire datum exclusivity eu expire apixaban manufacture company party product finish facility plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codevelope jointly market sanofi october bms sanofi announce restructuring alliance follow loss exclusivity plavix avaproavalide major market information alliance sanofi restructuring strategic alliance item financial statementsnote alliance composition matter patent expire eu regulatory datum exclusivity protection expire july europe national patent specifically claim bisulfate form clopidogrel expire plavix face generic competition globally obtain bulk requirement clopidogrel bisulfate sanofi prior january company sanofi finish product respective facility effective january company long finish clopidogrel bisulfate facility research development invest heavily research development rd believe critical longterm competitiveness major rd facility new jersey connecticut research development carry facility world include belgium uk india site supplement internal drug discovery development program alliance collaborative agreement help bring new product pipeline drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product management continue emphasize leadership innovation productivity quality strategy success research development activity concentrate research development effort follow disease area significant unmet medical need oncology human immunodeficiency virus hivacquire immunodeficiency syndrome aid hepatitis immunologic disorder cardiovascular fibrotic disease continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation eu foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase ii phase iii clinical trial design specifically support new drug application particular indication assume trial successful phase clinical trial involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase ii clinical trial involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical trial conduct confirm phase ii result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate rd process typically take fourteen year long approximately year spend phase iii latestage development consider rd program phase iii significant rd program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval failure rate compound enter phase ii development approximately compound enter phase iii development approximately total research development expense include cost discovery research preclinical development early latestage clinical development drug formulation postcommercialization medical support market product proportionate allocation enterprisewide cost appropriate cost research development spend billion billion billion include payment thirdparty collaboration contract end employ approximately people rd activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage rd program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual rd expense year individual investigational compound market product represent rd expense year list latestage investigational compound phase iii clinical trial regulatory review potential indication investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound patent coverage highlight include patent term patent term extension grant asunaprevir asunaprevir oral small molecule ns protease inhibitor phase iii development commence treatment hepatitis c virus infection currently registrational process japan patent cover asunaprevir composition matter expire daclatasvir daclatasvir oral small molecule nsa replication complex inhibitor phase iii development commence treatment hepatitis c virus infection currently registrational process japan eu patent cover daclatasvir composition matter expire bms bms oral small molecule nonnucleoside nsb inhibitor phase iii development commence treatment hepatitis c virus infection patent cover bms composition matter expire peginterferon lambda peginterferon lambda novel type interferon phase iii development commence hepatitis c virus infection patent cover peginterferon lambda composition matter expire elotuzumab elotuzumab humanized monoclonal antibody investigate anticancer treatment discover pdl biopharma facet biotech corporation facet spinoff facet subsequently acquire abbott laboratory abbott abbvie inc abbvie follow spinoff abbott elotuzumab alliance abbvie phase iii trial commence multiple myeloma abbvie own patent cover elotuzumab composition matter expire nivolumab nivolumab fully human monoclonal antibody bind program death receptor pd nkt cell investigate anticancer treatment phase iii trial commence nonsmallcell lung cancer renal cell cancer melanoma jointly patent ono cover nivolumab composition matter expire fda grant fast track designation nivolumab tumor type nonsmallcell lung cancer renal cell carcinoma advance melanoma february bms sell astrazeneca diabete business bms comprise global alliance include right ownership metreleptin metreleptin protein development treatment lipodystrophy currently registrational process follow table list potential additional indication andor formulation key marketed product phase iii development currently regulatory review key market product potential indication andor formulation baraclude pediatric extension eu reyataz pediatric extension fix dose combination cobicistat additional formulation erbitux additional indication esophageal cancer yervoy additional indication adjuvant melanoma prostate cancer nonsmallcell lung cancer small cell lung cancer additional indication melanoma combination nivolumab orencia additional indication lupus nephritis psoriatic arthritis eliquis additional indication vte treatment vte prevention follow key development currently expect occur respect significant pipeline program outcome timing expect development dependent number factor include thing availability datum outcome certain clinical trial acceptance presentation certain medical meeting andor action health authority undertake obligation publicly update information result new information future event asunaprevir potential approval japan hepatitis c virus infection plan submission hepatitis c virus infection daclatasvir potential approval eu japan hepatitis c virus infection plan submission hepatitis c virus infection nivolumab datum available clinical trial potential submission base registrational trial sprycel year datum available line cml yervoy data available phase iii study adjuvant melanoma eliquis potential approval vte treatment vte prevention strategic alliance enter strategic alliance party transfer right develop manufacture market andor sell pharmaceutical product own party alliance include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance involve share research development cost risk incur research development expense compound lead revenue generating product reduce profitability alliance product generally low profit alliance product share alliance partner actively pursue arrangement view alliance important complement discovery development commercialization activity strategic alliance party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure number alliance agreement permit alliance partner terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse alliance agreement sign strategic alliance typically contain provision provide party right terminate alliance short notice general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant strategic alliance material result operation cash flow material financial condition liquidity customary pharmaceutical industry term strategic alliance generally co extensive exclusivity period vary countrybycountry basis significant current alliance currently market product investigational compound describe current market productsinlicense otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement exclude certain asian country portion agreement amend expire expect loss product exclusivity april agreement expire european union eu countries june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country otsuka principal thirdparty product sale united kingdom germany france spain italy certain european country bms principal thirdparty product sale exclusive distributor exclusive right sell abilify remain territory alliance revenue recognize bms share total net sale party customer territorie bms contractual share begin january bmss contractual share change percentage total net product sale set forth table assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale december bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract annual net product sale bms share net product sale billion billion billion billion billion billion billion billion billion excess billion uk germany france spain italy certain european country otsuka principal bms contractual share thirdparty net product sale country alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer bms recognize net product sale certain country exclusive distributor product exclusive right sell abilify term abilify agreement amend purchase active pharmaceutical ingredient product otsuka perform finish manufacturing sale otsuka thirdparty customer term extension agreement pay otsuka million amortize reduction alliance revenue expect loss exclusivity april otsuka receive royalty base total net product sale otsuka responsible expense related commercialization abilify amendment otsuka assume responsibility provide funding sale force effort effective january consideration bm pay otsuka million january responsible funding certain operating expense million million million eu otsuka reimburse bms sale force effort provide march otsuka assume responsibility provide funding sale force effort eu effective april abilify agreement expire april june eu countries country exclusive right sell abilify agreement expire later april loss exclusivity country portion abilify agreement oncology agreement describe include changeofcontrol provision acquire acquire company compete product abilify new company assume abilify agreement amend oncology agreement currently exist acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right abilify agreement amend price accord predetermine schedule agreement provide event generic competitor abilify option terminate abilify april amendment agreement previously amend remain force exercise option receive payment otsuka accord predetermine schedule oncology agreement terminate time ii oncology agreement continue truncated period accord predetermine schedule early termination abilify agreement immediate notice case voluntary bankruptcy ii minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event challenge otsuka patent right marketbymarket basis event market product direct competition abilify termination expiration abilify agreement retain right abilify recognize total revenue abilify billion billion discussion oncology agreement otsuka current market productsinternally discover discussion strategic alliance otsuka item financial statementsnote alliance gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility certain activity relate commercialization atripla canada eu certain european country gilead recognize atripla revenue canada countries europe alliance revenue recognize atripla include bulk efavirenz component atripla calculate differently eu follow loss exclusivity sustiva eu alliance revenues defer related alliance receivable recognize atripla sell thirdparty customer recognize efavirenz alliance revenues billion billion billion related atripla net product sale joint venture arrangement company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version party component product appear market party right terminate joint venture acquire right combination product canada year terminate party continue receive percentage net product sale base contribution bulk component atripla retain right product enter licensing agreement gilead develop commercialize fixeddose combination contain reyataz gileads cobicistat pharmacoenhance boost agent currently phase iii clinical trial increase blood level certain hiv medicine potentially allow pill daily dose cobicistat currently registrational process fda discussion strategic alliance gilead item financial statementsnote alliance lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux canada japan egfr agreement respect erbitux net product sale north america lilly receive distribution fee base flat rate net product north america plus reimbursement certain royalty pay lilly company lilly share half profit loss evenly japan merck kgaa receive half profit loss japan party share royalty payable party pursuant formula set forth commercialization agreement purchase north american commercial requirement bulk erbitux lilly agreement expire erbitux north america september early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance retain rights erbitux north america share codevelopment copromotion right erbitux merck kgaa japan agreement sign october expire lilly merck kgaa merck japan lilly ability terminate agreement determine commercially unreasonable continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer head neck cancer december recognize net product sale erbitux million million million discussion strategic alliance lilly item financial statementsnote alliance sanofi september bms sanofi restructure term codevelopment cocommercialization agreement discuss effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico alliance plavix market continue unchanged december term original alliance arrangement describe exchange right assume sanofi bms receive quarterly royalty january december terminal payment sanofi million end pursuant master restructuring agreement company return sanofi right clopidogrel irbesartan market exception clopidogrel puerto rico company continue act operating partner majority control interest exist local arrangement territory territory b exception clopidogrel puerto rico terminate mutual agreement product continue sell local country entity territory addition sanofi assume marketing authorization product extent currently hold company affiliate result sanofi assume control activity relate distribution commercialization medical affair clopidogrel irbesartan region pursuant master restructuring agreement relate alliance agreement sanofi assume company manufacture supply obligation irbesartan product end company manufacture bulk clopidogrel long finish clopidogrel product facility company retain right intellectual property develop alliance necessary fulfill continue obligation alliance arrangement agreement sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside tradename karveakarvezide plavix copromote certain country outside tradename plavix comarkete certain country outside tradename iscover prior worldwide alliance operate framework geographic territory cover certain european asian country refer territory cover puerto rico canada australia certain latin american country refer territory b sanofi act operating partner territory own financial control interest territory ownership interest territory territory b act operating partner own majority control interest territory consolidate partnership result territory b territory b manage separate set agreement plavix puerto rico products australia mexico brazil colombia argentina separate set agreement avaproavalide puerto rico territory territory partnership exist supply finish product country territory manage contract certain central expense market research development royalty country territory b structured local affiliate sanofis local affiliate comarket separate brand ie affiliate operate independently compete sell product different trademark copromote single brand ie product trademark begin royalty receive sanofi territory b optout market development royalty present total revenue recognize total revenue territory b territory comarkete country billion billion billion alliance terminate sanofi event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day ii material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice discussion strategic alliance sanofi item financial statementsnote alliance current market productsinternally discover otsuka simultaneously extension abilify agreement april company otsuka enter oncology agreement sprycel ixempra ixabepilone include japan eu market oncology territory beginning fee pay otsuka annually base follow percentage annual net product sale sprycel ixempra net product sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million begin otsuka copromote sprycel japan begin copromote eu market oncology agreement expire respect sprycel ixempra include changeofcontrol provision acquire abilify agreement describe discussion abilify agreement otsuka current market productsinlicense discussion strategic alliance otsuka item financial statementsnote alliance addition january grant otsuka exclusive right japan develop commercialize onglyza agreement entitle receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan june otsuka assign right onglyza exception specific transition service kyowa hakko kirin khk consent assignment bms waive right copromote onglyza japan bms supply finish saxagliptin khk february sell astrazeneca diabete business comprise global alliance include right ownership onglyza seeitem financial statementsnote asset heldforsale discussion astrazeneca january enter worldwide japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement forxiga sglt agreement bms astrazeneca pharmaceutical lp whollyowne subsidiary astrazeneca enter alliance worldwide development commercialization amylin portfolio product include bydureon byetta symlin kombiglyze codevelope astrazeneca saxagliptin agreement exclusive right develop sell onglyza japan license otsuka december june assign otsuka khk describe february sell astrazeneca diabete business comprise global alliance include right ownership onglyza forxiga bydureon byetta symlin metreleptin seenote assets heldforsale information astrazeneca terminate exist alliance agreement connection sale enter new agreement include transitional service agreement supply agreement development agreement supply agreement continue manufacture onglyza kombiglyze forxiga discussion strategic alliance astrazeneca item financial statementsnote alliance investigational compound development internally discover pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover prevention treatment atrial fibrillation venous thromboembolic vte disorder pfizer fund development cost depend study receive million upfront milestone licensing payment pfizer date include million receive january receive additional million pfizer development regulatory milestone meet company share commercialization expense profit loss equally global basis discussion strategic alliance pfizer item financial statementsnote alliance investigational compound developmentinlicense abbvie august grant exclusive right facet biotech corporation abbvie codevelopment cocommercialization elotuzumab humanized monoclonal antibody investigate treatment multiple myeloma term agreement fund development cost elotuzumab commercialization abbvie share profit loss pay tiere royalty outside solely responsible commercialization elotuzumab addition abbvie receive milestone payment base certain regulatory event sale threshold achieve investigational compound developmentinternally discover ono september bms ono enter alliance agreement alliance agreement nivolumab antipd human monoclonal antibody investigate anticancer treatment subject alliance agreement alliance agreement enter ono medarex whollyowne subsidiary company alliance agreement alliance agreement ono grant bms exclusive right develop commercialize manufacture product contain nivolumab country world japan korea taiwan ono remain responsible development commercialization ono entitle receive certain salesbase royalty follow regulatory approval territory exclude country connection alliance agreement bms enter alliance ono grant certain commercialization right ono ono share expense profit loss orencia japan alliances february bms reckitt benckiser group plc reckitt enter year alliance overthecounterproduct sell primarily mexico brazil reckitt receive right sell distribute market product certain responsibility relate regulatory matter cover territory bm receive royalty net product sale exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include market authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance price determine base multiple net product sale plus cost remain inventory hold bms time option exercise asset previously transfer reckitt revert bms option exercise reckitt november case closing expect occur nonrefundable upfront alliance proceed million receive bms allocate right transfer reckitt million fair value option purchase remain asset million item financial statementsnote alliance information alliance february bms medicine company enter year alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc medicine company receive right sell distribute market recothrom global basis year certain responsibility relate regulatory matter cover territory bm exclusively supply recothrom medicine company pursuant supply agreement cost plus markup receive royalty net product sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include recothrom bla relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple revenue plus cost remain inventory hold bms time option exercise asset previously transfer medicine company revert bms option exercise medicine company february august case closing expect occur february nonrefundable upfront alliance proceed million receive bms allocate right transfer medicine company million fair value option purchase remain asset million item financial statementsnote alliance information alliance licensing arrangement addition strategic alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz merck efavirenz certain compound outlicense party development commercialization include obtain acquisition entitle receive milestone payment compound regulatory process royalty base net product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example eu japan certain country regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term eu japan china provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection region china questionable datum protection law enforceable certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file new drug application nda medicine biological product biologic license application bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file abbreviate nda anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph iv certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluates maa provide recommendation european commission ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu country process place simultaneously product market eu country process complete company market new product pricing reimbursement procedure month year complete eu product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent eu list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general eu law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity china china medicines new chemical entity generally afford year datum exclusivity approve indication dosage uncertainty china exclusivity law result generic competition china market generic copy receive regulatory approval datum exclusivity patent expiration currently unlike china patent term restoration compensate patent term lose regulatory process general chinese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside eu japan china wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eu develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical government regulation price constraint field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information product provide information response unsolicite inquiry doctor medical professional manage care organization operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new product new use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation cardinal health inc amerisourcebergen corporation business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler distributor maintain inventory level month demand ima include large wholesaler expire december subject certain termination provision number define country outside establish scale distributor model medically necessary drug available patient continue marketing authorization trademark product contract service fullservice distributor provide distribution logistic regulatory pharmacovigilance sale advertising promotion certain product contract clearly define term condition service provide supply firm order period monitor incountry sale forecast ensure reasonable inventory level product sale maintain fully continuously meet demand product distributor territory responsibility sale distributorbase country represent company total revenue competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service research development new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer eu regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion revenue product short period time rate revenue decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number eu country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribed key primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval ec obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control eu countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market uk germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states eu regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential eu different national pricing reimbursement law lead significant parallel trade flow healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase march government enact healthcare reform legislation sign law patient protection affordable care act hr reconciliation bill contain package change healthcare bill legislation make extensive change current system healthcare insurance benefit intend broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business new healthcare law implement example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion b drug pricing program public health service act begin require provide percent discount brandname drug patient fall medicare coverage gap refer donut hole require pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare discussion rebate program item management discussion analysis financial condition result operationstotal revenue critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing government regulation price constraint pharmaceutical manufacturing facility locate puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts continue capital investment facility rely party manufacture supply portion active ingredient necessary manufacture product include baraclude sustiva franchise erbitux yervoy reyataz abilify kombiglyze orencia eliquis avalide plavix begin february follow sale diabete business astrazeneca astrazeneca assume manufacturing responsibility bydureon byettato maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturer manufacture orencia thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet complex processing requirement biologic business performance prospect negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million million capital project undertake specifically meet environmental requirement addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee december employ approximately people include approximately employee process transfer astrazeneca sale diabete business february item financial statementsnote asset heldforsale discussion foreign operation significant operation outside conduct subsidiary distributor geographic breakdown total revenue table caption geographic area item financial statementsnote business segment information discussion total revenue geographic area item management discussion analysis financial condition result operationstotal revenue international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net unfavorable impact growth rate revenue predict certainty future change foreign exchange rate effect growth rate revenue attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument fair value measurement bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption addition information sustainability program available website responsibility caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation financial condition face intense competition manufacturer include innovative medicine lowerprice generic product bms dependent uptake market expansion market brand new indication product extension copromotional activity alliance partner deliver future growth competition include lowerpriced generic version product major challenge internationally face patent expiration increasingly aggressive generic competition competition include new product develop competitor low price real perceive superior efficacy benefit safety risk profile competitive product ii technological advance patent attain competitor iii clinical study result product competitor product iv business combination competitor major customer v compete interest external partnership develop bring new product market experience limited market access real perceive difference value proposition product compare competitor possible lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize period market exclusivity country market exclusivity expire generic version product approve market usually substantial rapid decline product revenue market exclusivity product base patent right andor certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain eu member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file market addition patent environment unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version product approve market addition prior expiration datum exclusivity competitor seek regulatory approval submit clinical trial datum obtain marketing approval manufacturer generic product increasingly seek challenge patent expire face earlierthanexpecte competition generic company product time patent cover key product sustiva baraclude currently subject patent litigation case generic manufacturer choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation example face generic competition baraclude time follow federal court decision invalidate composition matter patent february assurance particular product enjoy market exclusivity period time appear estimate disclose addition country india allow competitor manufacture sell generic version brand product know compulsory licensing negatively impact protection afford company increase pricing pressure restriction abroad manage care organization institutional purchaser government agency program negatively affect revenue profit margin product continue subject increase pressure portfolio relate market access pricing rebate restriction eu region world include limit rule practice manage care organization institutional governmental purchasers ii judicial decision governmental law regulation medicare medicaid healthcare reform include patient protection affordable care act iii potential impact pharmaceutical reimbursement medicare formularie product pricing general iv delay gain reimbursement v government price erosion mechanism europe country result deflation pharmaceutical product pricing vi collection delay government fund public hospital vii impact pricing parallel trade border viii development technology andor industry practice directly indirectly impact reimbursement policy practice thirdparty payer ix limited market access real perceive difference value proposition product compare compete product experience difficulty delay development commercialization new product develop commercialize new product include inherent risk uncertainty compound product appear promise development fail reach market expect optimal timeframe fail reach market approve product extension additional indication include efficacy safety concern delay denial regulatory approval delay difficulty produce product commercial scale excessive cost manufacture ii failure enter successfully implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product iv failure product achieve maintain commercial viability v change regulatory approval process cause delay denial new product approval observe recent trend food drug administration fda delay approval decision new product announce action date month long regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning product obtain acquisition result significant impairment process research development intangible asset certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally natural manmade disaster sabotage research development labs compound library andor loss key molecule intermediary negatively impact product development cycle failure execute business strategy adversely impact growth profitability biopharmaceutical company focus innovative product significant unmet medical need oncology virology immunology specialty cardiovascular disease able consistently maintain rich pipeline internal research development transaction party support future revenue growth competition major pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction able successfully realize expect efficiency effectiveness change structure operation specialty care strategy include recent reorganization research development organization commercial operation evolution support function enterprise service organization ongoing continuous improvement initiative addition realize synergy expect benefit acquisition divestiture merger alliance restructure strategic initiative long expect complete encounter difficulty include need regulatory approval applicable unable support grow currently market product successfully execute launch newly approve product advance latestage pipeline manage change transformational issue manage cost effectively operate result financial condition negatively impact addition failure hire retain personnel right expertise experience critical operation adversely impact execution business strategy public announcement datum clinical study news development relate latestage immunooncology compound likely cause significant volatility stock price development key immunooncology compound combination therapy delay discontinued stock price decline significantly evolve specialty care biopharmaceutical company focus effort resource certain disease area oncology virology immunology specialty cardiovascular disease focus portfolio investor place heighten scrutiny latestage compound particular nivolumab important asset immunooncology portfolio expect receive significant datum clinical trial evaluate nivolumab fully human monoclonal antibody investigate anticancer treatment nonsmalllung cancer renal cell cancer melanoma tumor type combination approve cancer product yervoy announcement datum clinical study news development relate latestage immunooncology compound nivolumab likely cause significant volatility stock price furthermore announcement negative unexpected datum discontinuation development key immunooncology compound combination therapy delay anticipate timeline file regulatory approval likely cause stock price decline significantly assurance datum clinical study support file regulatory approval approve key immunooncology compound commercially successful business acquire underperform able successfully integrate exist business continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include research development manufacturing distribution sale marketing promotion information technology activity ii policy procedure process control compliance iii company culture iv compensation structure human resource activity v tax consideration depend certain key product revenue cash flow earning historically derive majority revenue earning key product heavily dependent product past year dependence profitability key product likely continue abilify revenue billion represent revenue reyataz sustiva franchise combine revenue billion represent revenue respectively baraclude orencia sprycel revenue total billion billion billion respectively reduction revenue product significantly negatively impact revenue cash flow earning change foreign law regulation negatively affect revenue profit margin subject new government law regulation negatively affect business operating result financial condition company additional healthcare reform initiative country include additional mandatory discount ii increase tax revenue country mean reduce debt change tax rate limit phasingout eliminate deduction tax credit modify tax collection process tax certain tax haven tax certain excess income intellectual property change rule earning repatriation change tax law iii new law regulation judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction iv change intellectual property law v change accounting standard vi increase datum privacy regulation enforcement vii emerge new regulatory requirement report payment value transfer healthcare professional include national physician payment transparency program viii potential impact importation restriction legislative andor regulatory change product labeling change market product result unexpected safety efficacy concern negative impact product revenue regulatory authority change label pharmaceutical product time include product market year change result additional datum postmarkete study headtohead trial adverse event report study identify biomarker objective characteristic indicate particular response product therapy study produce important additional information product new information add product label affect safety andor efficacy profile product lead potential product recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine labeling change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution manage care organization influential scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue product product return limit patient population go forward additionally certain study result especially headtohead trial affect product formulary listing adversely affect revenue experience difficulty delay manufacture distribution sale product product supply relate patient access negatively impact thing seizure recall product force closing manufacture plant ii supply chain continuity include natural manmade disaster facility critical supplier failure failure supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay iv failure sole source single source supplier provide necessary raw material supply finish good extend period time v failure thirdparty manufacturer supply finish product time vi construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation business interruption adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute ii adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act uk antibribery act iv recall withdrawal pharmaceutical product force closing manufacture plant v failure fulfill obligation supply contract government customer vi product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law viii environmental health safety matter iv tax liability depend party meet contractual regulatory obligation rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance information technology business unit functional service meet contractual regulatory obligation relation arrangement thirdparty provider locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact company operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act uk bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence increasingly dependent information technology system infrastructure face certain risk include cyber security datum leakage significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store system nonencrypte portable medium storage device experience business interruption information theft confidential information reputational damage industrial espionage attack malware cyber attack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue invest industry appropriate protection monitor practice datum information technology reduce risk continue monitor system ongoing basis current potential threat assurance effort prevent breakdown breach party provider database system adversely affect business social medium platform present risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment social network web site damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce external medium channel lead information loss structured process place secure protect information identify new point entry social medium continue expand present new challenge adverse change global regional local economic condition adversely affect profitability global economic risk pose significant challenge company growth profitability difficult mitigate world major economy hold historicallyhigh debt level experience slow growth high unemployment risk lie ahead include management debt level european sovereign debt crisis significant operation europe include manufacturing exposure customer credit risk europe include governmentguaranteed hospital receivables market payment receive time addition future pension plan funding requirement continue sensitive global economic condition relate impact equity market expose commercial risk economic factor control pose significant challenge underlie profitability change foreign currency exchange rate interest rate material adverse effect operating result liquidity significant operation outside revenue operation outside account approximately revenue expose fluctuation foreign currency exchange rate difficult mitigate expose change interest rate ability access money market andor capital market impede adverse liquidity market condition occur illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand addition theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business item b unresolved staff comment item property world headquarter locate park avenue new york ny lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe rest world total portion manufacturing location property own lease research development administration storage distribution information property item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item safety disclosure applicable ia executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti executive vice president president worldwide pharmaceutical chief executive officer director executive vice president chief operating officer worldwide pharmaceutical member senior management team executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charle bancroft vice president finance worldwide pharmaceutical executive vice president chief financial officer chief financial officer company member senior management team present executive vice president chief financial officer company giovanni caforio md senior vice president oncology executive vice president chief commercial senior vice president oncology global commercialization officer senior vice president oncology immunology global commercialization member senior management team president pharmaceuticals present executive vice president chief commercial officer joseph c caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller francis cuss mb bchir frcp senior vice president discovery exploratory clinical research executive vice president chief scientific officer senior vice president research member senior management team present executive vice president chief scientific officer brian daniels md senior vice president global clinical development senior vice president global development present senior vice president global development medical affair medical affair research development member senior management team john e elicker senior director investor relation senior vice president public affairs investor vice president investor relation relation senior vice president investor relation member senior management team present senior vice president public affairs investor relation france heller head strategic alliance novartis pharmaceutical senior vice president business development executive vice president exelixis member senior management team instructor stanford university present senior vice president business development sandra leung vice president corporate secretary act general counsel general counsel corporate secretary present general counsel corporate secretary member senior management team samuel j moe senior vice president worldwide strategy operation senior vice president strategic plan senior vice president strategy analysis present senior vice president strategic planning analysis member senior management team current position age employment history past year anne nielsen vice president senior counsel senior vice president chief compliance vice president associate general counsel ethic officer senior vice president deputy general counsel member senior management team present senior vice president chief compliance ethic officer louis schmukler senior vice president pharmaceutical operating unit wyeth pharmaceutical president global manufacturing supply inc member senior management team senior vice president specialtybiotechnology operating unit pfizer present president global manufacturing supply paul von autenrie vice president chief information officer senior vice president enterprise service chief senior vice president chief information officer information officer present senior vice president enterprise service chief information officer member senior management team ii item market registrant common stock stockholder matter market price bristolmyer squibb common stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present high low high low common quarter second quarter quarter fourth quarter holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow dividend share pay quarter indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february issuer purchase equity security follow table summarize surrender repurchase equity security month period end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea plan programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december total number share purchase total number share purchase publicly announce program different share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation b board director authorize repurchase billion common stock june board director increase authorization repurchase common stock additional billion repurchase program expiration date consider future repurchase item select financial datum year financial summary amount million share datum income statement dataa total revenue continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtc equity discussion item affect comparability result year item management discussion analysis financial condition result operationsnongaap financial measure b include current noncurrent marketable security c include current portion longterm debt item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global specialty care biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease license manufacture market distribute sell pharmaceutical product global basis comparability total revenue earning prior year period impact reduction share abilify aripiprazole revenue acquisition amylin expand diabetes alliance arrangement astrazeneca loss exclusivity plavix billion intangible asset impairment charge transition away plavix avaproavalide continue grow key brand shift strategic focus earlystage research development advanced immunooncology portfolio hepatitis c portfolio rest latestage pipeline february bms sell astrazeneca diabete business bms comprise global alliance include right ownership onglyza saxagliptin forxiga dapagliflozin bydureon exenatide extendedrelease injectable suspension byetta exenatide symlin pramlintide acetate metreleptin astrazeneca pay billion bm closing million milestone february approval farxiga dapagliflozin contingent regulatory salesbase milestone payment million royalty payment base net sale item financial statementsnote asset heldforsale discussion highlight follow table summarize financial information year end december dollar million share datum total revenue total expense earning income taxis provision forbenefit income taxis effective taxbenefit rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure nongaap financial measure business environment pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect revenue product include product efficacy safety price demand competition costeffectiveness marketing effectiveness market access product label quality control quality assurance manufacturing operation research development new product successfully compete healthcare industry demonstrate product offer medical benefit cost advantage new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future manufacture brand product price high generic product generic competition key challenge pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize market exclusivity period long protect patent subject new compete product form generic brand exclusivity loss experience significant reduction product sale short period time competitor seek approval biological product biologic license application bla file safety efficacy datum address challenge biologic manufacture involve complex process cost pharmaceutical operation healthcare legislation enact abbreviate path regulatory approval biosimilar version biological product path approval biosimilar product healthcare legislation significantly affect regulatory data exclusivity biological product legislation provide regulatory mechanism allow regulatory approval biologic drug similar necessarily generic copy innovative drug basis extensive datum require bla possible time reasonably assess impact biosimilar legislation company globally healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue march government enact healthcare reform legislation sign law patient protection affordable care act hr reconciliation bill contain package change healthcare bill continue experience additional financial cost certain change business healthcare law provision effective aggregate financial impact healthcare reform year depend number factor include limited pende implementation guidance potential change sale volume eligible new rebate discount fee expect increase number people healthcare coverage patient protection affordable care act region outside operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing example pricing freedom limited united kingdom uk operation profit control plan germany operation reference price system european country continue fiscal challenge healthcare payer include government agency reduce expect continue reduce cost healthcare action directly indirectly impose additional price restriction company face significant delay market access new product year elapse drug approval new medicine available country growth manage care organization mcos significantly impact competition healthcare industry mco seek reduce healthcare expenditure participant volume purchase longterm contractual discount pharmaceutical provider market potential create large pool participant marketing prescription drug mco important strategy company compete inclusion mco formulary generally successful key product include believe development manage care industry include go consolidation continue downward pressure price pharmaceutical biotechnology production process complex highly regulate vary widely product shift add manufacturing capacity usually lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic large percentage product portfolio continue maintain supply arrangement thirdparty manufacturer incur substantial investment increase internal capacity produce biologic commercial scale united states food drug administration fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts continue capital investment facility maintain competitive position market strive uphold position depend success discover develop deliver innovative costeffective product help patient prevail disease subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter item financial statementsnote legal proceeding contingency strategy transform bms leadingedge biopharma company focus exclusively discover develop deliver innovative medicine address unmet medical need continue evolve drive fundamental objective grow market product progress pipeline focus core therapeutic area oncology virology immunology specialty cardiovascular disease oncology pioneer innovative medicine area immunooncology unlock bodys immune system battle cancer yervoy ipilimumab immunooncology agent introduce treatment metastatic melanoma continue invest significantly deep pipeline innovative medicine area cover broad array cancer evolve commercial model grow market product portfolio manner consistent overall strategy oncology building success yervoy yield revenue nearly billion product sprycel dasatinib erbitux cetuximab oncology continue support key brand virology franchise reyataz atazanavir sulfate baraclude entecavir account approximately billion revenue addition invest orencia abatacept key brand immunology portfolio account approximately billion revenue additionally strongly commit eliquis apixaban novel oral anticoagulant launch globally february divest diabetes portfolio allow accelerate evolution business model lead specialty care biopharma company transaction allow focus resource growth opportunity drive great longterm value look ahead continue implement biopharma strategy drive growth key brand execute new product launch invest pipeline maintain culture continuous improvement pursue discipline capital allocation include business development product pipeline development manage research development rd program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth consider rd program enter phase iii development significant program constitute latestage development pipeline development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual rd expense individual investigational compound market product represent rd expense year expect latestage development program market latestage development program rd program potentially impact revenue earning year follow recent significant development market product latestage pipeline hepatitis c portfolio daclatasvir nsa replication complex inhibitor development asunaprevir n protease inhibitor development bms nsb nonnucleoside polymerase inhibitor development january company announce european medicine agency ema validate marketing authorization application maa use daclatasvir treatment adult chronic hepatitis c compensate liver disease include genotype application seek approval daclatasvir use combination agent include sofosbuvir treatment chronic hepatitis c ema validation mark start accelerate regulatory review process november company announce submission new drug application nda japan pharmaceutical medical device agency submission base result phase iii study demonstrate week alloral regimen daclatasvir asunaprevir achieve overall sustained virologic response week end treatment japanese patient chronic hepatitis genotype b interferon ineligibleintolerant nonresponder null partial interferonbased therapy april european association study liver amsterdam company announce new phase ii datum demonstrate week triple directacting antiviral treatment regimen daclatasvir asunaprevir bms show high rate sustain virologic response treatmentnave genotype chronic hepatitis c patient time point range week posttreatment fda designate tripledaa regiman breakthrough therapy treatment chronic hepatitis c baraclude entecavir oral antiviral agent treatment chronic hepatitis b december company announce fda grant additional month period exclusivity market baraclude february district court district delaware invalidate composition matter patent covering baraclude schedule expire item financial statementsnote legal proceeding contingency discussion company prepare legal action event teva pharmaceutical industries ltd teva choose launch generic product prior resolution company appeal sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment human immunodeficiency virus hiv february company announce fda grant additional sixmonth period exclusivity market sustiva exclusivity sustiva schedule expire march nivolumab fully human monoclonal antibody bind program death receptor pd nkt cell investigate anti cancer treatment october company announce longterm followup result lung cancer cohort n expand phase doserange study nivolumab result show sustained activity heavily pretreate patient nonsmallcell lung cancer define twoyear survival rate respectively dose cohort june company announce result study doserange phase trial evaluate safety antitumor activity nivolumab combine concurrently sequentially yervoy patient advance melanoma patient receive dose phase iii trial mgkg nivolumab mgkg yervoy concurrent regimen confirm objective response modify world health organization criteria responder tumor shrink time schedule clinical treatment assessment week include complete response sprycel dasatanib oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate sprycel strategic alliance otsuka december american society hematology company otsuka announce fouryear followup datum phase iii dasision study sprycel mg daily vs gleevec mg daily firstline treatment adult philadelphia chromosomepositive chronic phase chronic myeloid leukemia year sprycel patient vs gleevec patient achieve major molecular response additionally sprycel patient vs gleevec patient achieve bcrabl month consider optimal molecular response define treatment guideline european leukemianet guideline patient arm achieve response month improve overall survival progressionfree survival year versus year sprycel patient n gleevec patient n remain treatment yervoy ipilimumab monoclonal antibody treatment patient unresectable inoperable metastatic melanoma november ema approve use yervoy line chemotherapy nave advanced melanoma patient september european cancer congress result present pool analysis survival datum study patient metastatic locally advanced unresectable melanoma treat yervoy different dose regimen include investigational dose mgkg patient follow year analysis find plateau survival curve begin year patient follow year year patient alive september company announce result phase iii randomize doubleblind clinical trial study compare yervoy placebo follow radiation patient advance metastatic castrationresistant prostate cancer receive prior treatment docetaxel study primary endpoint overall survival reach statistical significance antitumor activity observe efficacy endpoint include progression freesurvival elotuzumab humanized monoclonal antibody investigate anticancer treatment elotuzumab strategic alliance abbvie inc abbvie june company abbvie announce update efficacy safety datum small randomize phase ii openlabel study patient previouslytreate multiple myeloma evaluate dose elotuzumab combination lenalidomide lowdose dexamethasone mgkg arm dose ongoing phase iii trial median progressionfree survival pfs time disease progression month median followup month objective response rate orr previously report median pfs month mgkg arm median followup month orr abilify aripiprazole antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka january european commission ec approve abilify treatment pediatric bipolar mania metreleptin protein development treatment lipodystrophy strategic alliance astrazeneca include sale diabetes business june company astrazeneca announce fda accept filing grant priority review designation bla july fda notify company partner astrazeneca require threemonth extension complete review datum support bla december company astrazeneca announce fda endocrinologic metabolic drug advisory committee emdac recommend metreleptin treatment pediatric adult patient generalize lipodystrophy ld emdac recommend metreleptin patient partial ld indication currently propose company astrazeneca remain committed pursue metreleptin treatment patient metabolic disorder associate partial ld company acknowledge emdac feedback continue work fda identify appropriate patient partial ld benefit metreleptin prescription drug user free act pdufa date date decision fda expect february farxigaxigduo dapagliflozin metformin hydrochloride oral sodiumglucose cotransporter sglt inhibitor treatment diabete strategic alliance astrazeneca include sale diabetes business january company astrazeneca announce xigduo grant marketing authorization european commission treatment type diabete eu january company astrazeneca announce fda approve farxiga improve glycemic control diet exercise adult type diabete september annual meeting european association study diabetes easd company astrazeneca announce result phase iii study evaluate dapagliflozin adult patient type diabete inadequately control combination treatment metformin plus sulfonylurea patient treat dapagliflozin add therapy metformin plus sulfonylurea demonstrate significant improvement glycosylate hemoglobin level hbac key secondary endpoint significant reduction fast plasma glucose body weight compare placebo week significant improvement observe seat systolic blood pressure week patient treat dapagliflozin compare placebo june company astrazeneca announce result twoweek phase iia pilot study evaluate farxiga add insulin adult patient suboptimally control type diabetes show mean daily blood glucose derive point glucose measurement trend downward treatment group day seven reduction total daily insulin dosing day seven observe farxiga march japanese ministry health labor welfare accept review regulatory submission farxiga treatment type diabete january chinas state food drug administration accept review regulatory submission farxiga treatment type diabetes onglyza saxagliptin oncedaily oral tablet treatment type diabete strategic alliance astrazeneca include sale diabetes business february fda announce request clinical trial datum investigate possible association use onglyzakombiglyze heart failure fda state request broad evaluation fda conduct type diabetes drug therapy cardiovascular risk september european society cardiology company astrazeneca announce result savor clinical trial adult patient type diabete study onglyza meet primary safety objective demonstrate increase risk primary composite endpoint cardiovascular death nonfatal myocardial infarction nonfatal ischemic stroke add patient current standard care anti diabetic therapy compare placebo onglyza meet primary efficacy endpoint superiority placebo composite endpoint patient treat onglyza experience improve glycemic control reduce development progression microalbuminuria year assess exploratory analysis subsequent meeting annual meeting easd additional subanalyse savor present subanalyse find increase rate hypoglycemia patient treat onglyza compare placebo add metformin monotherapy baseline subanalyse find high rate hypoglycemia onglyza group compare placebo group patient take sulfonylureas agent know cause hypoglycemia baseline addition subanalyse find rate adjudicationconfirme pancreatitis balanced onglyza placebo treatment group observe rate pancreatic cancer low patient onglyza arm versus patient placebo arm orencia abatacept fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy june company ono pharmaceutical co ltd announce japanese ministry health labour welfare approve subcutaneous formulation orencia treatment rheumatoid arthritis case exist treatment inadequate june company announce result year datum ample compare subcutaneous formulation orencia versus humira adalimumab background methotrexate biologic nave patient moderate severe rheumatoid arthritis ample meet primary endpoint measure noninferiority american college rheumatology improvement year orencia regiman achieve comparable rate efficacy versus humira regimen vs respectively eliquis oral factor xa inhibitor target stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorder eliquis strategic alliance pfizer december company pfizer announce fda accept review supplemental new drug application eliquis treatment deep vein thrombosis dvt pulmonary embolism pe reduction risk recurrent dvt pe pdufa date august november european medicines agency accept review application eliquis treatment dvt pe prevention recurrent dvt pe september european society cardiology esc congress company pfizer announce result posthoc subanalysis phase iii aristotle trial evaluate eliquis compare warfarin patient type valvular heart disease vhd eligible enrollment aristotle trial include mitral regurgitation mitral stenosis aortic regurgitation aortic stenosis tricuspid regurgitation valve surgery result subanalysis consistent result overall aristotle trial demonstrate eliquis compare warfarin reduce stroke systemic embolism cause few major bleed event reduce allcause mortality nvaf patient vhd august esc company pfizer announce result posthoc subanalysis phase iii aristotle trial show comparable rate clinical event versus warfarin treatment arm day period follow procedure require temporary discontinuation anticoagulant prior follow procedure july company pfizer announce fda accept review supplemental new drug application eliquis prophylaxis deep vein thrombosis lead pulmonary embolism adult patient undergo hip knee replacement surgery pdufa date march june company pfizer announce result phase iii amplify trial evaluate eliquis versus current standard care treatment acute venous thromboembolism publish online new england journal medicine present international society thrombosis haemostasis congress amsterdam result show eliquis demonstrate comparable efficacy significantly low rate major bleed patient compare current standard care company pfizer announce result prespecifie subanalysis aristotle trial publish circulation peer review journal american heart association trend subgroup analysis consistent overall study result demonstrate eliquis superiority versus warfarin reduction stroke systemic embolism number major bleed event mortality patient nvaf eliquis receive regulatory approval reduction risk stroke systemic embolism patient nvaf south korea january israel russia february mexico colombia april eliquis receive regulatory approval prevention venous thromboembolic event adult patient undergo elective hip knee replacement surgery china january mexico april result operation total revenue composition change revenue follow year end december vs vs total revenue analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange united states europe rest world othera na na na na total total revenue include royalty alliancerelate revenue product sell regional commercial organization change excess single country outside contribute total revenue period present general business seasonal change revenue periods attribute volume reflect exclusivity loss plavix avaproavalide march partially offset increase demand key product amylinrelate product revenue follow completion acquisition august change revenue attribute price result reduction share abilify aripiprazole revenue impact partially offset high average net selling price abilify key product change revenue attribute price result high average net selling price abilify key product partially offset reduction share abilify revenue key product discussion total revenue key product revenue europe increase volume growth key product amylinrelate product revenue follow transition nonus operation second quarter favorable foreign exchange partially offset restructure sanofi agreement item financial statementsnote alliance discussion revenue decrease primarily unfavorable foreign exchange low revenue certain mature brand divestiture generic competition generic competition plavix avaproavalide partially offset volume growth key product revenue period continue negatively impact fiscal challenge european country healthcare payer include government agency reduce expect continue reduce healthcare cost action directly indirectly impose additional price reduction measure include limited mandatory discount rebate restrictive measure revenue rest world increase volume growth key product partially offset restructure sanofi agreement unfavorable foreign exchange particularly japan generic competition mature brand revenue rest world decrease generic competition plavix avaproavalide low revenue mature brand generic competition divestiture partially offset volume growth key product revenue increase high royalty result restructure sanofi agreement alliance revenue attribute mature brand overthecounter product alliance revenue increase enhance royaltyrelate revenue high revenue attribute active pharmaceutical ingredient supply agreement result divestiture manufacture facility restructure alliance agreement revenue expect decline expiration certain royalty alliance agreement item financial statementsnote alliance discussion alliance february bms sell astrazeneca diabete business bms comprise global alliance include right ownership onglyza forxiga bydureon byetta symlin metreleptin total revenue product billion item financial statementsnote asset heldforsale discussion recognize revenue net grosstonet adjustment describe critical accounting policy share certain abilify atripla revenue reflect net grosstonet adjustment alliance revenue present grosstonet adjustment table share abilify atripla grosstonet adjustment approximately billion billion billion change grossto net adjustment impact additional rebate discount require healthcare reform reduction share abilify revenue activity end reserve balance significant category grosstonet adjustment follow healthcare chargeback rebate related government cash contract medicaid sale dollar million program discount discount rebate return adjustment total balance january provision relate sale current period prior period return payment amylin acquisition impact foreign currency translation balance december provision relate sale current period prior period return payment assetsrelate liability heldforsale impact foreign currency translation balance december reconciliation gross product sale net product sale significant category grosstonet adjustment follow year end december change dollar million vs vs gross product sale grosstonet adjustment chargeback related government program cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet adjustment net product sale change excess grosstonet adjustment rate primarily function change revenue mix contractual legislative discount rebate grosstonet adjustment decrease chargeback relate government program cash discount medicaid rebates decrease period result low plavix revenue follow loss exclusivity manage healthcare rebate contract discount increase primarily amylinrelate net product sale manage healthcare rebate contract discount decrease primarily result low plavix revenue follow loss exclusivity manage healthcare rebate contract discount decrease million reduction estimate medicare coverage gap discount attributable prior period rebate receive actual invoice nonrenewal plavix contract discount medicare program january estimate medicaid rebate attributable prior period sale reduce million million receive actual invoice information certain state medicaid administrative office provision sale return high result loss exclusivity plavix avaproavalide sale return reserve product million million december respectively determine consider factor include estimate inventory level distribution channel accordance company policy product eligible return month prior month product expiration adjustment reserve require future revise estimate assumption include actual return expect occur adjustment increase primarily high government rebate nonus market adjustment increase copay coupon program key product revenue key product represent total revenue follow table present international revenue key product percentage change prior period foreign exchange impact compare prior period commentary detail reason significant variance key product provide change attributable year end december change foreign exchange dollar million vs vs vs vs key product virology baraclude entecavir nonus reyataz atazanavir sulfate nonus sustiva efavirenz franchise nonus oncology erbitux cetuximab nonus sprycel dasatinib nonus yervoy ipilimumab na nonus na neuroscience abilify aripiprazole nonus metabolic bydureon exenatide extendedrelease injectable suspension na na na na na na na nonus na na na na byetta exenatide na na na na na na na nonus na na na na forxiga dapagliflozin na na na na na na na na na na na nonus na na na na na onglyzakombiglyze saxagliptinsaxagliptin metformin nonus change attributable year end december change foreign exchange dollar million vs vs vs vs key product continue immunoscience nulojix belatacept na nonus na na orencia abatacept nonus cardiovascular avaproavalide irbesartanirbesartanhydrochlorothiazide nonus eliquis apixaban na na na na na nonus na na plavix clopidogrel bisulfate nonus mature product nonus change excess baraclude oral antiviral agent treatment chronic hepatitis b revenues periods increase high average net selling price high demand experience rapid significant decline revenue begin possible generic competition follow federal court decision february invalidate composition matter patent international revenue increase period high demand partially offset unfavorable foreign exchange reyataz protease inhibitor treatment hiv revenue decrease low demand partially offset high average net selling price revenue increase high average net selling price international revenue increase high demand time government purchase certain country international revenue decrease unfavorable foreign exchange time government purchase certain country low demand result compete product sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sell alliance gilead revenue increase high average net selling price partially offset low demand revenue increase primarily high demand high average net selling price international revenue increase favorable foreign exchange international revenue decrease unfavorable foreign exchange erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux strategic alliance lilly revenue periods remain relatively flat sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate sprycel strategic alliance otsuka revenue periods increase primarily high demand high average net selling price international revenue period increase primarily high demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patient unresectable inoperable metastatic melanoma revenue periods increase high demand revenue favorably impact recognition million revenue previously defer sufficient historical experience estimate sale return develop international revenue period increase high demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka revenue decrease reduction contractual share revenue partially offset high average net selling price revenue increase high average net selling price million reduction bmss share estimate customer rebate discount attributable base actual invoice receive international revenue period increase primarily high demand international revenue impact unfavorable foreign exchange bydureon onceweekly glp receptor agonist treatment type diabete strategic alliance astrazeneca revenue include result completion amylin acquisition august transition international operation bydureon majority market lilly complete second quarter item financial statementsnote alliance discussion byetta twice daily glucagonlike peptide glp receptor agonist treatment type diabete strategic alliance astrazeneca revenue include result completion amylin acquisition august transition international operation byetta majority market lilly complete second quarter item financial statementsnote alliance discussion forxiga oral sodiumglucose cotransporter sglt inhibitor treatment type diabete strategic alliance astrazeneca forxiga launch treatment type diabete limited number eu market fourth quarter continues launch eu market onglyzakombiglyze know eu onglyzakomboglyze oncedaily oral tablet treatment type diabete strategic alliance astrazeneca revenue increase primarily high average net selling price revenue increase primarily high overall demand high average net selling price international revenue increase period primarily high demand partially offset unfavorable foreign exchange nulojix fusion protein novel immunosuppressive activity target prevention kidney transplant rejection nulojix approve launch eu orencia fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy revenue periods increase primarily high demand high average net selling price international revenue period increase primarily high demand partially drive launch subcutaneous formulation orencia certain eu market begin second quarter partially offset unfavorable foreign exchange avaproavalide know eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy sanofi alliance revenue long recognize follow restructure sanofi agreement effective january negative sale increase sale return reserve avalide revenue decrease loss exclusivity march international revenue impact change attribute restructure sanofi agreement item financial statementsnote alliance discussion international revenue decrease low demand include generic competition certain eu markets canada eliquis oral factor xa inhibitor target stroke prevention atrial fibrillation prevention treatment vte disorder eliquis strategic alliance pfizer eliquis launch europe japan canada quarter continues launch market reduction risk stroke systemic embolism patient nvaf eliquis approve eu vte prevention launch limited number eu country begin plavix platelet aggregation inhibitor alliance sanofi revenues periods decrease loss exclusivity international revenue impact change attribute restructure sanofi agreement item financial statementsnote alliance discussion international revenue negatively impact generic clopidogrel product eu canada australia mature product include product include lose exclusivity major market overthecounter brand royalty relate revenue revenue decrease periods generic erosion certain product partially offset sale symlin follow completion amylin acquisition august international revenue increase certain alliance partially offset continue generic erosion product international revenue decrease continued generic erosion certain brand unfavorable foreign exchange international revenue expect decline expiration certain royalty alliance agreement estimate endus demand pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception estimate level inventory distribution channel excess month hand product material date indicate product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand direct customer september december level inventory hand primarily order pattern pharmacist france reyataz month inventory hand internationally september compare month inventory hand december level inventory hand government purchasing pattern brazil generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q expense change dollar million vs vs cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset na incomeexpense total expense change excess cost product sell cost product sell include material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost settlement foreign currency forward contract hedge forecast intercompany inventory purchase transaction essentially cost manage global manufacturing supply organization cost product include royalty profit sharing attribute license product alliance amortization acquire develop technology cost business combination milestone payment occur regulatory approval cost product sell vary period result product mix particularly result royalty profit sharing expense connection alliance price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility certain cost denominate foreign currency cost product sell percentage total revenue change primarily attribute favorable product mix result royalty profit sharing expense connection alliance cost product sell relatively flat high profit sharing expense connection alliance include result amylin acquisition august high net amortization cost attributable amylin acquisition partially offset low royalty follow loss exclusivity plavix avaproavalide high impairment charge decrease cost product sell primarily attribute low sale volume follow loss exclusivity plavix avaproavalide result low royalty connection sanofi alliance favorable foreign exchange partially offset impairment charge discuss high amortization cost result amylin acquisition net amortization amylin alliance proceed impairment charge million recognize include million relate continued competitive pricing pressure reduction undiscounte project cash flow carrying value develop technology intangible asset remain million impairment charge relate abandonment manufacturing facility result outsource manufacturing process marketing sell administrative marketing selling administrative expense include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global corporate organization finance law information technology human resource marketing selling administrative expense decrease accelerated vest stock option restrict stock unit relate amylin acquisition million low pharmaceutical company fee assess federal government reduction sale relate activity certain product coincide respective lifecycle partially offset high spending support launch new key product additional spending follow amylin acquisition marketing sell administrative expense increase primarily result amylin acquisition million include accelerate vest stock option restrict stock unit partially offset reduction salesrelated activity plavix avaproavalide marketing sell administrative expense impact favorable foreign exchange advertising product promotion advertising product promotion expense include medium sample direct consumer program advertise product promotion expense increase primarily high spending recently launch key product advertising product promotion expense decrease primarily low spending promotion plavix avaproavalide abilify certain mature brand coincide product life cycle research development research development expense include salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost total research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost facility information technology employee stock compensation cost appropriate cost upfront licensing fee relate payment achievement regulatory contractual milestone include certain expense share alliance partner base contractual agreement expense manage global research development organization approximately billion billion billion total spend respectively attribute development activity remainder attribute preclinical research activity expense vary period number reason include time upfront milestone licensing payment research development expense decrease primarily prior year impairment charge accelerate vest stock option restrict stock unit relate amylin acquisition upfront milestone licensing payment partially offset additional cost follow amylin acquisition high clinical grant spending research development expense increase primarily million expense relate amylin acquisition include accelerate vest amylin stock option restrict stock unit million partially offset favorable foreign exchange net impact upfront milestone licensing payment iprd impairment charge refer specify item include nongaap financial measure amount attribute period iprd impairment charge relate project previously acquire medarex inc medarex acquisition inhibitex inc inhibitex acquisition include million relate fv nucleoside inhibitor reduction shinglesassociate pain result unfavorable clinical trial result decision cease development impairment charge bms intangible asset billion impairment charge recognize development bm inx compound acquire acquisition inhibitex treat hepatitis c virus infection discontinue interest patient safety item financial statement note goodwill intangible asset information intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment critical accounting policy discussion incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation chargesrecoverie equity net income affiliate outlicense intangible asset impairment gain sale product line business asset income receive alliance partner net pension curtailment settlement incomeexpense interest expense increase period high average borrowing provision restructure primarily attributable employee termination benefit employee termination cost million incur result workforce reduction european country employee reduction primarily attribute sale force reduction result restructure sanofi otsuka agreement streamline operation challenge market condition europe litigation chargesrecoverie include million share apotex damage award concern plavix equity net income affiliate primarily related international partnership sanofi europe asia decrease period result restructure sanofi agreement continues negatively impact generic competition plavix europe asia equity net income affiliate decrease continued impact generic competition international plavix net sale conversion certain territory optout market impact unfavorable foreign exchange outlicense intangible asset impairment charge relate asset acquire medarex zymogenetics inc zymogenetics acquisition result unfavorable clinical trial result andor abandonment program gain sale product line businesse asset primarily relate sale building mexico sale mature brands income alliance partner include royalty amortization upfront milestone licensing payment relate certain alliance decrease plavix net product sale result low development royalty owe sanofi royalty receive sanofi europe asia present revenue begin result restructure sanofi agreement item financial statementsnote alliance discussion pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan charge include acceleration portion unrecognize actuarial loss similar charge occur future item financial statementsnote pension postretirement postemployment liability detail change primarily relate high acquisition cost loss debt repurchase sale tax reimbursement gain debt repurchase higher upfront milestone licensing receipt income taxis dollar million earning income taxis provision forbenefit income taxis effective taxbenefit rate change effective tax rate primarily million tax benefit attribute capital loss deduction result tax insolvency inhibitex impact deduction reduce effective tax rate percentage point change result tax benefit attributable high impairment charge include million impairment charge bms intangible asset favorable earning mix high low tax jurisdiction attributable low plavix revenue less extent internal transfer intellectual property fourth quarter legal enactment research development tax credit high charge contingent tax matter historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation ireland puerto rico favorable tax rate ireland puerto rico grant schedule expire prior noncontrolle interest item financial statementsnote alliance discussion plavix avaproavalide partnership sanofi territory cover america decrease noncontrolle interest period result exclusivity loss plavix avaproavalide march summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning attributable noncontrolle interestnet taxis nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item significant andor unusual nature evaluate individual basis similar charge gain item recognize prior period reasonably possible reoccur future period nongaap information intend portray result baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar millions accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell stock compensation accelerate vest amylin award process standardization implementation cost marketing sell administrative stock compensation accelerate vest amylin award upfront milestone licensing payment iprd impairment research development impairment charge bms intangible asset provision restructure gain sale product line business asset pension settlement acquisition alliance relate item litigation chargesrecoverie upfront milestone licensing receipt outlicense intangible asset impairment loss debt repurchase incomeexpense increase pretax income income tax item specify tax benefita income taxis increase net earning specify tax benefit relate capital loss deduction specify tax benefit relate release tax reserve specify prior period reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms gaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation gaap net earning attributable bms gaap specify item net earning attributable bms nongaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net debt position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing current portion longterm debt longterm debt net debt position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis start issue commercial paper meet nearterm domestic liquidity requirement average commercial paper outstanding million weightedaverage interest rate maximum monthend commercial paper outstanding million outstanding borrowing december continue issue commercial paper asneede basis february bms sell astrazeneca diabete business bms comprise global alliance term agreement astrazeneca upfront payment billion company bms receive million milestone payment february approval farxiga seeitem financial statementsnote asset heldforsale discussion january notice provide holder note bms exercise option redeem note entirety february outstanding principal note million investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard item financial statementsnote financial instrument fair value measurement separate billion fiveyear revolve credit facility syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december october bms issue billion senior unsecured note register public offering consist million aggregate principal note million aggregate principal note million aggregate principal note proceed general corporate purpose include repayment commercial paper borrowing additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivable direct customer currently believe economic condition eu material impact liquidity cash flow financial flexibility mechanism limit overall credit exposure additional source liquidity sell trade receivable party principally wholesaler japan certain governmentbacked entity italy portugal spain sale trade receivables italy portugal spain million million million sale receivables japan million million million sale agreement allow recourse event uncollectibility retain interest underlie asset sell continue manage operate cash flow focus work capital item directly affect change sale volume receivables inventory account payable dollar million december december net trade receivables inventory account payable total credit rating moodys investor service longterm shortterm credit rating currently prime respectively longterm credit outlook revise stable negative september standard poor longterm shortterm credit rating currently respectively longterm credit outlook remain stable fitch lower longterm credit rating lower shortterm credit rating f f revise longterm credit outlook negative stable july stable negative december credit rating consider investment grade longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee pension contribution tax payment ordinary course business change cash provide operating activity period primarily attributable upfront milestone contingent alliance proceed million billion billion astrazeneca consideration enter amylin alliance million low operating cash flow million billion attribute plavix avaproavalide revenue reduction follow loss exclusivity product change include work capital requirement period investing activity change cash investing activity primarily attributable cash fund acquisition amylin billion inhibitex billion amira million cash sale purchase maturity marketable security million million primarily attribute time investment time deposit corporate debt security maturity great day cash generate sale purchase maturity marketable security billion cash partially fund acquisition investing activity include litigation recovery million financing activity change cash financing activity primarily attributable cash repurchase common stock million billion billion board director authorize repurchase billion june board director increase authorization repurchase stock additional billion repurchase program expiration date consider future repurchase dividend payment billion dividend declare common share december declare quarterly dividend common share expect pay dividend year share dividend decision quarterly basis board director proceed issuance senior unsecured note billion billion million principal note mature repay repayment debt assume amylin acquisition billion management periodically evaluate potential opportunity repurchase certain debt security terminate certain interest rate swap contract prior maturity cash outflow relate repurchase debt million million proceed termination interest rate swap contract million proceed stock option exercise million exclude million cash retain excess tax benefit million exclude million cash retain excess tax benefit million exclude million cash retain excess tax benefit proceed vary period base fluctuation market value stock relative exercise price stock option factor contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability totalc include estimate future interest payment shortterm longterm debt security include accrue interest payable recognize consolidated balance sheet consist primarily accrue interest shortterm longterm debt accrue periodic cash settlement derivative b uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table item financial statementsnote income taxis detail c table exclude future contribution pension postretirement postemployment benefit plan require contribution contingent numerous factor include minimum regulatory funding requirement fund status plan uncertainty future obligation exclude table contribution international plan expect million item financial statementsnote pension postretirement postemployment liability detail addition commit billion aggregate potential future research development milestone payment party inlicense development program earlystage milestone define milestone achieve phase iii clinical trial comprise million total commit latestage milestone define milestone achieve post phase iii clinical trial comprise billion total commit payment agreement generally payable achievement certain developmental regulatory milestone specific timing predict addition certain royalty obligation calculate percentage net product sale agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation item financial statementsnote alliance information alliance discussion contractual obligation item financial statementsnote pension postretirement postemployment liability note financial instrument fair value measurement note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly gross revenue current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard july financial accounting standard board issue update clarify exist guidance presentation unrecognize tax benefit qualifying tax benefit carryforward exist include unrecognized tax benefit present reduction defer tax asset liability update require adopt annual period interim reporting period begin december early adoption permit reduction defer tax asset expect approximately million critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate recognize revenue persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix eg medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience addition total revenue discussion analysis significant category grosstonet sale adjustment grosstonet adjustment follow category grosstonet adjustment involve significant estimate judgment information obtain external source chargeback related government program business participate program government entity significant department defense department veteran affair party include cover entity b drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag cash discount certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag manage healthcare rebate contract discount rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan contract counterpartie hospital group purchasing organization globally begin rebate medicare program include discount company brandname drug patient fall medicare coverage gap rebate require department defense tricare retail pharmacy refund program estimate unpaid unbilled rebate discount present liability million reversal estimate medicare coverage gap discount occur receipt actual invoice medicaid rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual retroactive january minimum rebate medicaid drug sale increase medicaid rebate extend drug manage medicaid plan begin march estimate unpaid unbilled rebate present liability estimate medicaid rebate attributable prior period revenue reduce million million sale return product typically eligible return month prior month product expiration accordance policy estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product instance expect precipitous decline demand follow loss exclusivity estimate product return present liability reserve establish plavix avaproavalide million million december respectively consider relevant factor estimate future retail wholesale inventory work occur loss exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic category defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product use information external source information external source estimate grosstonet adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citigroup pension discount curve plan plan pension expense determine weightedaverage discount rate present value benefit obligation december pension plan determine discount rate discount rate determine plan pension expense reduce additional expense increase approximately million assumed discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately million expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liabilitie business combination goodwill intangible asset acquire business combination licensing transaction billion represent total asset include billion include asset heldforsale december asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill fair value intangible asset include iprd typically determine income method method starts forecast net cash flow risk adjust estimate probability technical regulatory success iprd adjust present value appropriate discount rate reflect risk associate cash flow stream asset value market participant view different specific bms view valuation process complex require significant input judgment internal external source valuation required finalize oneyear period consider fact evidence available acquisition date complex judgmental matter applicable valuation process summarize unit account intangible asset value single global asset multiple asset jurisdiction indication consider development stage expect level incremental cost obtain additional approval risk associate development time benefit expect derive future expect patent live jurisdiction intention promote asset global brand estimate useful life asset life expect contribute meaningful cash flow determine consider pertinent matter associate asset include expect regulatory approval date unapproved exclusivity period legal regulatory contractual provision effect obsolescence demand competition economic factor include barrier entry probability technical regulatory success ptrs rate ptrs rate determine base industry average consider respective program development stage disease indication adjust specific information datum know acquisition date subsequent clinical result internal external datum obtain alter ptrs rate materially impact estimate fair value intangible asset subsequent period leading impairment charge projection future revenue estimate consider factor initial market opportunity pricing sale trajectory peak sale level competitive environment product evolution future cost expense estimate consider historical market trend market participant synergy timing level additional development cost obtain initial additional regulatory approval maintain enhance product generally assume initial positive cash flow commence shortly receipt expect regulatory approval typically occur number year actual cash flow attribute project likely different assume projection subject multiple factor include trial result regulatory matter materially change ultimate commercial success asset significantly alter cost develop respective asset commercially viable product tax rate expect future income tax effect market participant tax rate recent valuation typically use tax rate applicable state taxis consider jurisdiction intellectual property hold location research manufacturing infrastructure consider earning repatriation likely tax consequence discount rate discount rate select consider risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset item financial statementsnote acquisition specific detail value assign asset acquire liability assume acquisition amylin inhibitex amira significant estimate utilize time valuation support fair value lead compound acquisition include estimate phase year discount useful life development ptrs rate project positive dollar million fair value rate utilize year acquisition date utilize cash flow commercialize product bydureon na na na byetta na na na symlin na na na recothrom na na na iprd bms inx na phase ii metreleptin na phase iii na phase impairment goodwill goodwill billion december goodwill test annually impairment enterprise level assess qualitative factor perform quantitative analysis determine likely fair value exceed carry value example qualitative factor assess current year include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year positive negative influence relevant factor assess individually aggregate result conclude additional quantitative testing require discussion goodwill acquire inprocess research development intangible asset item financial statementsnote accounting policiesgoodwill acquire inprocess research development intangible asset intangible asset include iprd intangible asset billion december include license million develop technology right billion capitalize software million iprd million intangible asset test impairment current fact circumstance warrant review iprd require test annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize charge billion include billion charge result discontinue development bms project previously acquire medarex inc inhibitex acquisition result unfavorable clinical trial result additional development cost extend development period decision cease development recognize charge million relate medarex project development cease iprd closely monitor assess period impairment addition iprd commercial asset subject impairment example impairment charge million recognize related nonkey product prior acquisition continue competitive pricing pressure operate dynamic market regulatory environment event occur cause expectation change quickly lead potential impairment charge specific intangible asset material carry value december expose potential impairment include iprd asset peginterferon lambda million phase iii development treatment hepatitis c virus millionin phase ii development treatment fibrosis asset monitor change expectation initial valuation property plant equipment property plant equipment test impairment current fact circumstance warrant review additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion net valuation allowance billion december billion net valuation allowance billion december defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure believe likely defer tax asset realize addition defer tax asset relate federal state capital loss million recognize december carry year carry forward year realization carryforward dependent generate sufficient capital gain prior expiration million valuation allowance establish item december taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore prior mead johnson nutrition company mead johnson splitoff follow transaction occur internal spinoff mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement example mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset agree indemnify mead johnson certain taxis relate business prior completion ipo create restructure facilitate ipo establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contract manage foreign exchange risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset portion exposure designate hedge change fair value derivative recognize earning incur estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december realize appreciation negatively affect earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge recognize foreign currency translation component accumulate comprehensive incomeloss net investment fall equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information item financial statementsnote financial instrument fair value measurement interest rate risk fixedtofloate interest rate swap contract designate fairvalue hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million exclude effect counterparty credit risk realize fair value reduction affect earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk material certain european governmentbacke entity high risk default identify monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio addition entity specific factor historically exposure limited factoring receivables credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis credit exposure trade receivables greece portugal italy spain approximately million december approximately governmentbacke entity monitor investment counterpartie objective minimize concentration credit risk investment policy place limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation term agreement post collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statement note financial instrument fair value measurement bristolmyers squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense earning income taxis provision forbenefit income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit available sale security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense asset heldforsale total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing current portion longterm debt account payable accrue expense defer income accrue rebate return income taxis payable dividend payable liability related asset heldforsale total current liability pension postretirement postemployment liability defer income income taxis payable deferred income taxis liabilitie longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization net defer income taxis stockbase compensation impairment charge proceed amylin diabetes alliance change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software proceed sale business invest activity purchase business net cash acquire net cash investing activity cash flow financing activity shortterm debt borrowingsrepayment proceed issuance longterm debt repayment longterm debt interest rate swap contract termination issuance common stock repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company refer bristolmyer squibb bms company control majorityowned subsidiary intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity arrangement material variable interest entity period present use estimate preparation financial statement require use management estimate assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation net product sale alliance revenue previously present aggregate net sale consolidate statement earning present separately revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty base party sale recognize earn accordance contract term party sale reliably measurable collectability reasonably assure refer note alliance detail alliance provision time revenue recognition expect sale return discount rebate estimate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation provision recognize reduction revenuewhen new product extension exist line product historical experience product similar therapeutic category revenue defer right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include treasury security government agency security bank deposit time deposit money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include equity net income affiliate incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment length time extent market value cost financial condition investee inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique level fair value input include discount value estimate future cash flow capitalize software eligible cost obtain internal use software significant system project capitalize amortize estimate useful life software insignificant cost obtain software project expense incur business combination business acquire consolidate obtain control acquiree fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill legal audit business valuation business acquisition cost expense incur goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility judgment estimate impact restructuring plan include future termination benefit exit cost incur action place actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur derivative financial instrument derivative principally management interest rate foreign currency exposure hold trading purpose derivative recognize fair value change fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive incomeloss oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long probable occur gain loss immediately recognize earning nonderivative instrument primarily euro denominate longterm debt designate hedge net investment foreign affiliate effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party research development recognize net reimbursement connection alliance agreement recently issue accounting standard july financial accounting standard board issue update clarify exist guidance presentation unrecognize tax benefit qualifying tax benefit carryforward exist include unrecognized tax benefit present reduction defer tax asset liability update require adopt annual period interim reporting period begin december early adoption permit reduction defer tax asset expect approximately million note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible development delivery product market regional commercial organization distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation cardinal health inc amerisourcebergen corporation select geographic area information follow total revenue property plant equipment dollar millions united states europe rest world othera total total revenue include royalty alliancerelate revenue product sell regional commercial organization total revenue key product follow year end december dollar million virology baraclude entecavir reyataz atazanavir sulfate sustiva efavirenz franchisea oncology erbitux cetuximab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazoleb metabolic bydureon exenatide extendedrelease injectable suspension na byetta exenatide na forxiga dapagliflozin na onglyzakombiglyze saxagliptinsaxagliptin metformin immunoscience nulojix belatacept orencia abatacept cardiovascular avaproavalide irbesartanirbesartanhydrochlorothiazide eliquis apixaban plavix clopidogrel bisulfate mature product total revenue include million million million present alliance revenue b include million million million present alliance revenue note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage refer collaboration alliance partner alliance partner payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale thirdparty product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation amount payable bms alliance partner profit sharing royalty salesbase fee include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense advertising product promotion expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize short contractual term period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca plc astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense equity net income affiliate include incomeexpense payment bms alliance partner present cash flow operating activity select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative advertising product promotion research development incomeexpense net earning attributable noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include defer income classify liability related asset heldforsale million december specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify exclude certain asian country portion agreement amend expire expect loss product exclusivity april agreement expire european union eu countries june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country party actively participate joint executive governance operate committee otsuka assume responsibility provide funding sale force effort effective january amendment bms responsible funding certain operating expense annual limit bms purchase active pharmaceutical ingredient api otsuka complete manufacture product subsequent sale party customer certain country otsuka assume responsibility provide funding sale force effort eu effective april bms provide certain service include distribution customer management pharmacovigilence otsuka principal thirdparty product sale united kingdom uk germany france spain italy begin march bms principal thirdparty product sale exclusive distributor exclusive right sell abilify remain territory alliance revenue recognize bmss share total net sale thirdparty customer territorie bmss contractual share begin january bmss contractual share change percentage total net sale set forth table assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale december bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract annual net sale bms share net sale billion billion billion billion billion billion billion billion billion excess billion united kingdom germany france spain italy begin march bmss contractual share thirdparty net sale country alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer term amendment bm pay otsuka million amortize reduction alliance revenue expect loss exclusivity april unamortized balance include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify bms otsuka alliance sprycel ixempra ixabepilone japan eu party actively participate governance committee bms control decision make party copromote product bms responsible development manufacture product bm principal endcustomer product sale fee pay otsuka base follow percentage annual net sale sprycel ixempra net sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million extension oncology alliance include changeofcontrol provision case acquisition bms acquire company compete product abilify new company assume abilify agreement amend oncology alliance exist today acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right bms abilify agreement amend agreement provide event generic competitor abilify january bms option terminate abilify april amendment agreement previously amend remain force bms exercise option bms receive payment otsuka accord predetermine schedule oncology alliance terminate time ii oncology alliance continue truncated period accord predetermine schedule summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenuesa total revenue payment tofrom otsuka cost product sell oncology fee royalty amortization intangible asset cost product supply cost reimbursement tofrom otsuka select alliance balance sheet information december dollar million asset extension payment include amortization extension payment reduction alliance revenue million astrazeneca bms astrazeneca diabete alliance consist worldwide codevelopment commercialization agreement agreement cover onglyza relate combination product sell name second agreement cover forxiga commercialize farxiga relate combination product agreement cover amylin portfolio product bydureon byetta symlin pramlintide acetate metreleptin currently development certain asset own amylin include manufacturing facility onglyza agreement exclude japan enter separate agreement coexclusive license right product product underlying agreement grant astrazeneca exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal endcustomer product sale substantially country alliance agreement determine right transfer astrazeneca standalone value right sell separately bms party astrazeneca receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive billion nonrefundable upfront payment astrazeneca consideration enter amylin alliance astrazeneca exercise option equal governance right certain key strategic financial decision amylin alliance pay bms million consideration payment account deferred income amortize base relative fair value predominant element include alliance estimate useful life intangible asset relate bydureon estimate useful life year byetta estimate useful life year symlin estimate life year metreleptin estimate useful life year amylin manufacture plant estimate useful life year amortization present reduction cost product sell alliance asset acquire shortly commencement alliance astrazeneca entitle share proceed sale asset amortization acquire amylin intangible asset manufacturing plant present cost product sell bms entitle reimbursement capital expenditure relate acquire amylin manufacturing facility bms astrazeneca share certain tax attribute relate amylin alliance bms receive million nonrefundable upfront milestone licensing payment relate onglyza date bms receive million non refundable upfront milestone licensing payment relate forxiga date amortization onglyza forxiga defer income include income onglyza forxiga commercial product commencement alliance party equally share commercialization development expense profit loss summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenue payment tofrom astrazeneca cost product sell profit sharing amortization defer income cost reimbursement tofrom astrazeneca recognize cost product sell marketing sell administrative advertising product promotion research development incomeexpense amortization defer income provision restructuring select alliance cash flow information nonrefundable upfront milestone licensing payment receive amylinrelate product forxiga select alliance balance sheet information december dollar millions defer income nonrefundable upfront milestone licensing receiptsa amylinrelate product onglyza forxiga include liability relate asset heldforsale december february bms sell astrazeneca diabete business bms comprise global alliance include right ownership onglyza forxiga bydureon byetta symlin pramlintide acetate metreleptin transaction include share amylin result transfer manufacturing plant intellectual property relate onglyza forxiga future purchase bmss manufacturing facility locate mount vernon indiana early month follow closing transaction party terminate exist alliance agreement connection sale enter new agreement include transitional service agreement supply agreement development agreement note asset heldfor sale information gilead bms gilead sciences inc gilead joint venture canada europe develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint venture consolidate gilead party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada api bulk form party complete finishing atripla canada joint venture sell distribute atripla principal thirdparty customer sale europe gilead affiliate sell distribute atripla principal thirdparty customer sale party long coordinate joint promotional activity alliance revenue recognize atripla include bulk efavirenz component atripla base relative ratio average respective net selling price truvada sustiva alliance revenue defer related alliance receivable recognize combined product sell thirdparty customer europe follow loss exclusivity sustiva effective january percentage atripla net sale bms recognize base ratio difference average net selling price atripla truvada atripla average net selling price alliance continue party terminate arrangement patent expiration occur atripla truvada sustiva agreement terminate gilead launch generic version sustiva bms launch generic version truvada event gilead terminate agreement loss exclusivity sustiva bms receive quarterly royalty payment month follow termination payment month follow termination equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price second year follow termination payment bms reduce respectively atripla net sale multiply price ratio describe bms continue supply sustiva cost plus markup joint venture threeyear period party elect terminate supply arrangement summarize financial information relate alliance follow year end december dollar million revenue gilead alliance net product sale alliance revenue total revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer revenue lilly bms commercialization agreement eli lilly company lilly lilly november acquisition imclone system incorporate imclone codevelopment promotion erbitux expire september party actively participate joint executive committee operating committee share responsibility research development alliance resource infrastructure lilly responsible supply product bms distribution sale bms responsible promotional effort product north america lilly right copromote expense bms codevelopment copromotion right canada japan bms principal thirdparty customer sale north america commercialization agreement bms pay lilly distribution fee base flat rate net sale erbitux north america plus share certain royalty pay lilly japan bms share right erbitux agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly march bms lilly terminate arrangement necitumumab imcf right return lilly discover imclone necitumumab fully human monoclonal antibody alliance bms lilly bms amortize million license acquisition cost associate erbitux alliance agreement summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale payment tofrom lilly cost product sell distribution fee royalty amortization intangible asset cost product supply cost reimbursement tofrom lilly incomeexpense japan commercialization fee select alliance balance sheet information december dollar million intangible asset nonrefundable upfront milestone licensing payment bms acquire amylin pharmaceuticals inc amylin august note acquisition information amylin previously enter settlement termination agreement lilly alliance global development commercialization byetta bydureon exenatide product party agree transition responsibility product amylin transition operation complete time acquisition transition nonus operation exenatide product majority market complete april terminate lilly exclusive right nonus commercialization exenatide product promissory note assume acquisition amylin aggregate billion repay lilly sanofi september bms sanofi restructure term codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico alliance plavix market continue unchanged december term original alliance arrangement describe exchange right assume sanofi bms receive quarterly royalty january december terminal payment sanofi million end ongoing dispute company resolve include million payment bms sanofi relate avalide supply disruption accrue begin royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenue million development optout royalty income million million include incomeexpense development royalty expense million million include incomeexpense royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate additionally equity net income affiliate include million profit defer prior restructure agreement alliance revenue attribute supply irbesartan api sanofi million million million supply arrangement irbesartan expire prior restructure bmss worldwide alliance sanofi codevelopment cocommercialization avaproavalide plavix operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia territory partnership manage central expense market research development royalty supply finish product individual country bms act operating partner own majority control interest territory cover americas australia consolidate country partnership result territory sanofis share result reflect noncontrolle interest bms recognize net product sale comarkete country outside territory eg italy irbesartan germany greece spain sanofi act operating partner own majority control interest territory cover europe asia bms ownership interest territory summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi cost product supply cost product sell royalty equity net income affiliate incomeexpense noncontrolle interest pretax select alliance cash flow information distribution tofrom sanofi noncontrolle interest distribution sanofi investment affiliate select alliance balance sheet information december dollar million investment affiliate territory cover europe asiaa noncontrolle interest include alliance receivables follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income cost product sell territory cover europe asia include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory remain current asset current liability consist thirdparty trade receivables inventory amount bms sanofi purchase inventory royaltie expense reimbursement pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms pfizer fund development cost depend study company share commercialization expense profit loss equally global basis certain country bm global commercialization network pfizer commercialize eliquis pay bms compensation base percentage net sale enter agreement coexclusive license right product grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal endcustomer product sale substantially country determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive million nonrefundable upfront milestone licensing payment relate eliquis date include million receive january receive additional million development regulatory milestone amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing cost reimbursement tofrom pfizer incomeexpense amortization defer income select alliance cash flow information nonrefundable upfront milestone licensing payment receipts select alliance balance sheet information december dollar millions defer income reckitt benckiser group bms reckitt benckiser group plc reckitt enter threeyear alliance overthecounterproduct sell primarily mexico brazil net sale product approximately million reckitt receive right sell distribute market product certain responsibility relate regulatory matter cover territory bm receive royalty net sale product exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include market authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine base multiple sale plus cost remain inventory hold bms time option exercise asset previously transfer reckitt revert bms option exercise reckitt november case closing expect occur nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt million fair value option purchase remain asset million good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability change estimate fair value option liability significant allocate right transfer reckitt amortize alliance revenue contractual term alliance revenue million include product supply royalty medicine company february bms medicine company enter twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc net product sale recothrom million medicine company receive right sell distribute market recothrom global basis year certain responsibility relate regulatory matter cover territory bm exclusively supply recothrom medicine company pursuant supply agreement cost plus markup receive royalty net sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include recothrom biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time option exercise asset previously transfer medicine company revert bms option exercise medicine company february august case closing expect occur february nonrefundable upfront proceed million receive bms allocate unit account include right transfer medicine company million fair value option purchase remain asset million good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability change estimate fair value option liability significant allocate right transfer medicine company amortize alliance revenue contractual term alliance revenue million include product supply royalty valeant october bms pharmaswis sa whollyowne subsidiary valeant pharmaceuticals international inc valeant enter alliance certain mature brand product europe valeant receive right sell distribute market product europe december certain responsibility relate regulatory matter cover territory alliance term bms exclusively supply product valeant pursuant supply agreement cost plus markup bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale option exercise right transfer valeant revert bms option exercise valeant january june case closing expect occur december nonrefundable upfront proceed million receive bms allocate unit account include right transfer valeant million fair value option purchase remain asset million good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include accrue expense change estimate fair value option liability significant allocate right transfer valeant amortize alliance revenue contractual term alliance revenue million million include product supply net product sale recognize transitional period million million note acquisition amylin pharmaceuticals inc acquisition august bms complete acquisition outstanding share amylin biopharmaceutical company focus discovery development commercialization innovative medicine treat diabete metabolic disease acquisition cost million include expense bms obtain commercialization right amylin primary commercialize asset bydureon onceweekly diabete treatment byetta daily diabete treatment glucagonlike peptide glp receptor agonist approve certain country improve glycemic control adult type diabete bms obtain commercialization right symlin amylinomimetic approve adjunctive therapy mealtime insulin treat diabete goodwill generate acquisition primarily attribute expansion diabetes franchise iprd attribute metreleptin analog human hormone leptin study develop treatment diabetes andor hypertriglyceridemia pediatric adult patient inherit acquire lipodystrophy estimate useful life cash flow utilize value metreleptin assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result note asset heldforsale discussion sale company diabetes business include amylin astrazeneca comprise global diabetes alliance inhibitex inc acquisition february bms complete acquisition outstanding share inhibitex inc inhibitex clinicalstage biopharmaceutical company focus develop product prevent treat infectious disease acquisition cost million include expense bms obtain inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c virus infection goodwill generate acquisition primarily attribute potential offer portfolio therapy choice hepatitis virus infection provide additional level sustainability bmss virology pipeline iprd primarily attribute inx inx expect effective combination therapy assume market participant inherently maintain franchise synergy attribute maximize cash flow exist virology pipeline asset cash flow utilize value inx include synergy assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result august company discontinue development inx interest patient safety result company recognize noncash pretax impairment charge billion relate iprd intangible asset quarter information discussion impairment charge note goodwill intangible asset amira pharmaceuticals inc acquisition september bms complete acquisition outstanding share amira pharmaceuticals inc amira million cash plus separate contingent million payment achievement certain development salesbase milestone contingent payment fourth quarter purchase price amira include estimate fair value total contingent consideration million record liability acquisition cost million include expense amira privatelyheld biotechnology company primarily focus discovery development therapeutic product treatment cardiovascular fibrotic inflammatory disease acquisition provide bms right develop commercialize complete phase clinical study remainder amira lysophosphatidic acid receptor antagonist program researcher fibrotic expertise preclinical autotaxin program goodwill generate acquisition primarily attribute acquire scientific expertise fibrotic disease allow expansion new therapeutic class total consideration transfer allocation acquisition date fair value asset acquire liability assume amylin inhibitex amira acquisition follow dollar million identifiable net asset amylin inhibitex amira cash marketable security inventory property plant equipment develop technology right iprd asset debt obligation liability defer income taxis total identifiable net asset goodwill total consideration transfer cash pay acquisition amylin include payment million outstanding common stockholder million holder stock option restrict stock unit include million attribute accelerate vest account stock compensation expense quarter result operation cash flow acquire company include consolidated financial statement acquisition date pro forma supplemental financial information provide impact acquisition material operating result year acquisition goodwill iprd intangible asset value acquisition nondeductible tax purpose note asset heldforsale february bms sell astrazeneca diabete business bms comprise global alliance include right ownership onglyza forxiga bydureon byetta symlin metreleptin transaction include share amylin previously acquire bms august result transfer manufacturing facility west chester ohio intellectual property relate onglyza forxiga future purchase bmss manufacturing facility locate mount vernon indiana early month follow closing transaction substantially employee dedicated diabetes business transfer astrazeneca closing transaction consideration transaction astrazeneca pay billion bm closing million milestone february approval farxiga contingent regulatory salesbase milestone payment million royalty payment base net sale addition astrazeneca payment million certain asset transfer include mount vernon manufacturing site diabete business china business treat single disposal group hold sale december writedown require fair value business cost sell exceed related carrying value follow asset liability diabete business heldforsale present separately bmss account december dollar million december asset receivables inventory defer income taxis current prepay expense property plant equipment goodwilla intangible asset asset total asset heldforsale liability shortterm borrowing current portion longterm debt account payable accrue expense defer income current accrue rebate return defer income noncurrent defer income taxis noncurrent liability total liability relate asset heldforsale allocation goodwill base relative fair value diabete business december divest company report unit stock asset purchase agreement contain multiple element deliver subsequent closing transaction element transaction determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method include china diabete business mount vernon manufacturing facility development agreement incremental discount attribute supply agreement remain consideration receive closing include calculation estimate net gain disposal contingent consideration include royalty milestone payment receive allocate underlying element transaction relative selling price basis amount allocate sale business immediately recognize amount allocate element recognize immediately defer extent element deliver note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructuring note litigation chargesrecoverie equity net income affiliate outlicense intangible asset impairment gain sale product line business asset income receive alliance partner net pension curtailment settlement incomeexpense note restructuring follow provision restructuring year end december dollar million employee termination benefit exit cost provision restructure restructuring charge include termination benefit workforce reduction manufacturing sell administrative research development personnel geographic region approximately follow table represent activity employee termination exit cost liability year end december dollar million liability january charge change estimate provision restructure foreign currency translation amylin acquisition liability relate asset heldforsale spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provisionbenefit effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate nontax deductible annual pharmaceutical company fee foreign tax effect certain operation ireland puerto rico switzerland state local taxis net valuation allowance federal state foreign contingent tax matter federal research development tax credit tax effect capital loss foreign change effective tax rate tax benefit million attributable capital loss deduction result tax insolvency inhibitex tax benefit attributable high impairment charge include million impairment charge bms intangible asset high charge contingent tax matter million million partially offset favorable earning mix high low tax jurisdiction primarily attributable low plavix revenue less extent impact internal transfer intellectual property fourth quarter favorable impact current year rate legal enactment research development tax credit retroactive reinstatement research development tax credit recognize million change effective tax rate tax benefit million attributable capital loss deduction result tax insolvency inhibitex favorable earning mix high low tax jurisdiction primarily attribute low plavix revenue million impairment charge bms intangible asset less extent internal transfer intellectual property partially offset contingent tax matter result million charge million benefit unfavorable impact current year rate delay legal enactment research development tax credit extend december change prior period estimate finalize tax return result million benefit defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward milestone payment license fee defer income capital loss federal net operating loss carryforward pension postretirement benefit state net operating loss credit carryforward intercompany profit inventory item federal tax credit carryforward foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning internal transfer intellectual property total defer tax asset valuation allowance net defer tax asset defer tax liability depreciation acquire intangible asset total defer tax liability defer tax asset net recognize asset heldforsale defer income taxis current deferred income taxis noncurrent foreign income taxis payable current liability relate asset heldforsale defer income taxis noncurrent total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization federal tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration capital loss available million carry carry forward foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life management establish valuation allowance defer tax asset likely realize december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal capital loss change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million taxis provide approximately billion undistributed earning foreign subsidiary undistribute earning indefinitely invest offshore december additional tax provision require earning repatriate future earning determine remit foreseeable future complexity tax law assumption practicable estimate amount income taxis provide result bms favorable tax rate ireland puerto rico grant schedule expire prior business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expense penalty expense uncertain tax benefit reduce deferred tax asset extent uncertainty directly relate asset recognize current non current foreign income taxis payable accrue interest penalty payable unrecognized tax benefit include current noncurrent foreign income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority include limited major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit bms anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms earning attributable unvested restricted share net earning attributable bms common shareholder earning share basic weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share dilute antidilutive weightedaverage equivalent share stock incentive plan note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize nonbinde quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include treasury security level input utilize observable price similar instrument nonbinde quote price identical similar instrument market active observable input corroborate market datum substantially term asset liability instrument include corporate debt security certificate deposit money market fund foreign currency forward contract interest rate swap contract equity fund fix income fund longterm debt additionally certain corporate debt security utilize thirdparty matrix pricing model use significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment significant unfunded commitment restriction redemption relate equity fix income fund december level derivative instrument value london interbank offer rate libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably periodtoperiod volatility underlie foreign currency underlie interest rate drive market condition duration contract credit adjustment volatility significant impact valuation interest rate swap change counterparty credit rating credit default swap spread level unobservable input little market datum available fair value write option sell asset certain business connection alliance agreement note alliance discussion base option pricing methodology consider revenue profitability projection volatility discount rate potential exercise price assumptionsthe fair value contingent consideration relate acquisition note acquisition estimate utilize model consider probability achieve milestone discount rate valuation model auction rate security ar float rate security frs portfolio base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity fair value ar frs material december financial asset liability measure fair value recur basis summarize december december dollar million level level level total level level level total cash cash equivalent money market security marketable security certificate deposit corporate debt security treasury security equity fund fix income fund ar frs derivative asset interest rate swap contract foreign currency forward contract derivative liability interest rate swap contract foreign currency forward contract write option liabilitiesa contingent consideration liabilityb write option liability million million include accrue expense liability respectively note alliance information b contingent consideration liability include liability note acquisition information follow table summarize activity financial asset utilize level fair value measurement write contingent write contingent option consideration ar option consideration ar dollar million liability liability frs liability liability frs fair value january addition new alliance unrealize gain sale fair value december availableforsale security follow table summarize availableforsale security gross gross unrealize unrealized gain loss amortize accumulate accumulate dollar million cost oci oci fair value december certificate deposit corporate debt security ar total december certificate deposit corporate debt security treasury security ar frs total availableforsale security include current marketable security million december noncurrent availableforsale corporate debt security mature year million december auction rate security mature year million december fair value option financial asset company invest equity fix income fund design offset change fair value certain employee retirement benefit investments equity fix income fund include current marketable security million million respectively december million million respectively december investment income result change fair value investment equity fix income fund million million qualifying hedge follow summarize fair value outstanding derivative december december dollar million balance sheet location notional fair value notional fair value derivative designate hedge instrument interest rate swap contract asset interest rate swap contract liabilitie foreign currency forward contract prepay expense foreign currency forward contract asset foreign currency forward contract accrue expense foreign currency forward contract liabilitie cash flow hedge foreign currency forward contract primarily utilize hedge forecast intercompany inventory purchase transaction certain foreign currency forward contract designate cash flow hedge effective portion change fair value temporarily report accumulate oci recognize earning hedge item affect earning net gain foreign currency forward contract expect reclassify cost product sell year include million pretax gain reclassify month notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december cash flow hedge accounting discontinue forecast transaction long probable occur originally forecast date day hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis ineffective portion change fair value include current period earning earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present net investment hedge nonus dollar borrowing million million designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain loss remeasurement debt recognize foreign currency translation component accumulate oci relate offset long term debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt swap underlie debt benchmark risk hedge record fair value effective interest rate pay fixedtofloate interest rate swap onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize earning reduction interest expense remain life debt fixedtofloate interest rate swap contract execute convert million notional fix rate variable rate debt fixedtofloate interest rate swap contract billion notional billion notional terminate generate total proceed million include accrue interest million debt obligation shortterm borrowing current portion longterm debt include december dollar millions bank draft shortterm borrowing current portion longterm debt total longterm debt current portion longterm debt include december dollar million principal value note euro note note note note euro note note debenture note debenture note note note note debenture mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount total current portion longterm debta longterm debt include liability relate asset heldforsale december include debt million float rate convertible senior debenture redeem holder par september fundamental change ownership occur debenture callable par time company debenture current conversion price equal conversion rate share principal subject certain antidilutive adjustment average commercial paper outstanding million weightedaverage interest rate maximum month end commercial paper outstanding million outstanding borrowing december fourth quarter billion senior unsecured note issue million aggregate principal note million aggregate principal note million aggregate principal note register public offer interest note pay semiannually note rank equally right payment bmss exist future senior unsecured indebtedness bms redeem note time predetermine redemption price net proceed note issuance million net discount million defer loan issuance cost million quarter billion senior unsecured note issue million aggregate principal note million aggregate principal note million aggregate principal note register public offer interest note pay semiannually note rank equally right payment bmss exist future senior unsecured indebtedness bms redeem note time predetermine redemption price net proceed note issuance million net discount million defer loan issuance cost million million principal note mature repay quarter substantially billion debt obligation assume acquisition amylin repay quarter include promissory note lilly respect revenue sharing obligation amylin senior note january notice provide holder note bms exercise option redeem note entirety february outstanding principal note million principal value longterm debt obligation million december million million million million remain million fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument debt repurchase debt repurchase activity include repayment amylin debt obligation follow dollar million principal carry value repurchase price notional interest rate swap contract terminate swap termination proceed total lossgain interest payment million million million net amount related interest rate swap contract bms separate billion fiveyear revolve credit facility syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december december million financial guarantee provide form standby letter credit performance bond standby letter credit issue financial institution support guarantee bms affiliate obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivables receivables include december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization asset heldforsale balance end year note inventory inventory include december dollar million finish good work process raw packaging material inventory inventory expect remain onhand year include asset million december million december note property plant equipment property plant equipment include december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment property plant equipment relate mount vernon indiana manufacturing facility approximately million december facility expect sell early month follow closing diabetes business transaction include asset heldforsale asset available immediate sale present condition expect sell year note alliance discussion sale diabete business depreciation expense million million million note goodwill intangible asset change carry goodwill follow december dollar million carry goodwill january acquisition inhibitex amylin asset heldforsale carrying goodwill december quarter purchase price allocation finalize amylin acquisition result million adjustment goodwill defer income taxis goodwill million allocate sale diabetes business include asset heldforsale seenote asset heldforsale discussion intangible asset include december december gross net gross net estimate carry accumulate carrying carry accumulate carry dollar million useful life amortization amortization license year develop technology right year capitalize software year total finitelive intangible asset iprd total intangible asset change intangible asset follow dollar million intangible asset carry january capitalize software addition acquisition amortization expense impairment charge asset heldforsale intangible asset net carrying december develop technology right million iprd million relate sale diabetes business reclassify asset heldforsale december note asset heldforsale discussion annual amortization expense intangible asset expect approximately million million million million million million bm announce discontinued development bm know inx nucleotide polymerase nsb inhibitor phase ii development treatment hepatitis c virus infection august decision interest patient safety base rapid thorough ongoing assessment patient phase ii study voluntarily suspend august bm acquire bms acquisition inhibitex february result termination development program million pretax impairment charge recognize iprd intangible asset impairment charge million recognize related continued competitive pricing pressure partial writedown fair value develop technology right relate previously acquire nonkey product note accrue expense accrue expense include december dollar million employee compensation benefit royaltie accrue research development restructure current pension postretirement benefit accrue litigation total accrue expense note sale rebate return accrual reduction trade receivable accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment accrue rebate return note deferred income defer income include december dollar millions upfront milestone licensing receipt atripla defer revenue gain saleleaseback transaction total defer income current portion noncurrent portion upfront milestone licensing receipt amortize expect life product information pertain upfront milestone licensing receipt defer revenue relate atripla seenote alliance defer gain saleleaseback transaction amortize remain lease term relate facility amortization defer income million million million deferred income million include liability relate asset heldforsale december seenote asset heldforsale discussion note equity common stock capital treasury stock excess par value retain noncontrolle dollar share million share par value stock earning share cost interest balance january net earning cash dividend declare stock repurchase program employee stock compensation plan comprehensive income attributable noncontrolle interest distribution balance december net earning cash dividend declare stock repurchase program employee stock compensation plan comprehensive income attributable noncontrolle interest distribution balance december net earning cash dividend declare stock repurchase program employee stock compensation plan distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method board director authorize repurchase billion common stock june board director increase authorization repurchase stock additional billion repurchase program expiration date consider future repurchase noncontrolle interest primarily relate plavix avaproavalide partnership sanofi territory cover america net earning attributable noncontrolle interest present net taxis million million million corresponding increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis activity include pretax income distribution relate partnership component comprehensive incomeloss follow dollar million pretax tax tax derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit available sale security unrealize gain foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit available sale security unrealize gain realize gainsd available sale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial gain amortizationb settlementsc pension postretirement benefit available sale security unrealize loss realize gainsd available sale security foreign currency translation reclassification net earning derivative qualify effective hedge recognize cost product sell b actuarial loss prior service costcredit amortize cost product sell research development marketing sell administrative expense c pension settlement curtailment recognize incomeexpense realize gainslosse available sale security recognize incomeexpense accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit available sale security foreign currency translation accumulate comprehensive incomeloss note pension postretirement postemployment liability company certain subsidiary sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation respectively fund policy contribute minimum require employee retirement income security act erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit creditcost define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss curtailment settlement total net periodic benefit creditcost pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement plan amendment actuarial lossesgain retiree drug subsidy benefit pay exchange rate loss benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy benefit pay exchange rate gain fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability fund status recognize accumulate comprehensive loss net actuarial lossesgain net obligation adoption prior service credit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit creditcost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year accumulate comprehensive loss reduce million result actuarial gain attribute benefit obligation million high expect return plan asset million actuarial gain result prevail equity fix income market condition increase interest rate expect return plan asset determine expect rate return calculate value asset refer marketrelated value fair value plan asset exceed marketrelated value million december difference assume actual return amortize marketrelated value straightline basis threeyear period gain loss result change actuarial assumption change discount rate difference assume actual experience difference actual expect return plan asset gain loss difference amortize market relate value amortize extent exceed high marketrelated value project benefit obligation respective plan majority remain actuarial loss amortize life expectancy plan participant plan year expect remain service period plan cost product sell research development marketing sell administrative expense amortization net actuarial loss prior service credit expect approximately million assumed healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate material impact service interest cost post retirement benefit obligation plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity security equity fund fix income fund corporate debt security venture capital limit partnership government mortgage back security treasury agency security shortterm investment fund insurance contract event drive hedge fund collateralize mortgage obligation bond state municipal bond asset back security real estate cash cash equivalent total plan asset fair value investment valuation policy investment class follow level input utilize quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include equity security equity fund real estate fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input include observable price similar instrument quote price identical similar instrument market active observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund event drive hedge fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end significant unfunded commitment restriction redemption relate investment value nav december corporate debt security government mortgage back security collateralize mortgage obligation bond asset back security treasury agency security state municipal bond classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available venture capital limit partnership classify level fair value hierarchy invest underlying security market value determine pricing model discount cash flow methodology similar technique significant unobservable input valuation methodology include discount rate earn interest taxis depreciation amortization ebitda multiple revenue multiple significant change input result significantly lower high fair value measurement insurance contract interest carry contract value approximate estimate fair value base fair value underlie investment insurance company insurance contract hold certain foreign pension plan valuation model corporate debt security government mortgage back security collateralize mortgage obligation bond asset back security classify level fair value hierarchy base estimate bid broker thirdparty vendor source utilize expect cash flow stream collateral value include assessment counterparty credit quality default risk discount rate overall capital market liquidity follow summarize activity financial asset utilize level fair value measurement venture capital limited insurance dollar million partnership contract total fair value january purchase sale settlement realize lossesgain unrealized gainslosse fair value december purchase sale settlement realize gain unrealize gain fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage venture capital limited partnership typically value month lag late available information bms common stock represent plan asset december contribution contribution pension plan million million million contribution international pension plan million million million aggregate contribution international plan expect approximately million estimate future benefit payment pension dollar million benefit benefit year saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan million million post employment benefit plan postemployment liability longterm disability benefit million million december respectively relate credit million expense million million termination indemnity plan international statutory termination obligation recognize undiscounted basis assume employee termination measurement date liability recognize obligation million million december respectively note employee stock benefit plan shareholder approve stock award incentive plan plan replace stock incentive plan share common stock reserve issuance pursuant stock plan option conversion prefer stock million december share available grant active plan adjust combination plan million december share stock option exercise share unit vest issue treasury stock share actually deliver participant connection award restriction lapse reduce number share reserve share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price common stock stock unit grant key employee subject restriction continuous employment restriction expire year period date grant compensation expense recognize vest period stock unit right receive stock end specify vest period voting right market share unit grant certain executive begin vest condition continuous employment vest date payout factor equals share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year longterm performance award year cycle deliver form target number performance share unit number share ultimately issue calculate base actual performance compare earning target performance criterion establish beginning year year performance cycle award annual goal maximum payout threshold target meet performance period payment plan annual period vest occur end year period stockbase compensation expense base award ultimately expect vest recognize vest period acceleration unvested stock option restrict stock unit connection acquisition amylin result stockbase compensation expense forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate stockbase compensation expense follow year end december dollar million stock option restrict stock market share unit longterm performance award amylin stock option restrict stock unit note total stockbase compensation expense income tax benefit sharebase compensation activity follow longterm performance stock option restrict stock unit market share unit award weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest total compensation cost relate sharebased payment award recognize weightedaverage period award expect recognize december follow longterm restrict market performance dollar million stock unit share unit awards unrecognize compensation cost expect weightedaverage period year compensation cost recognize additional information relate sharebased compensation award summarize follow amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit longterm performance award fair value option award vest year stock option restrict stock unit market share unit longterm performance award total intrinsic value stock option exercise year fair value restrict stock unit longterm performance award determine base closing trading price company common stock grant date fair value market share unit approximate closing trading price company common stock grant date estimate date grant consider payout formula probability satisfy market condition follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding exercisable number weightedaverage weightedaverage outstanding exercisable remain contractual exercise price aggregate range exercise price thousand life year share intrinsic value aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum rental commitment operate lease expense million million million sublease income material period present note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property atripla april teva pharmaceutical industries ltd teva file abbreviate new drug application anda manufacture market generic version atripla atripla single tablet threedrug regimen combine company sustiva efavirenz gileads truvada time company patent right cover sustivas composition matter method use challenge teva send gilead paragraph iv certification letter challenge orange bookliste patent atripla gilead file patent infringement action teva district court southern district new york sdny january company receive notice teva amend anda challenge additional orange bookliste patent atripla march company merck sharp dohme corp merck file patent infringement action teva sdny relate patent claim crystalline polymorph form efavirenz august company merck teva reach settlement relate efavirenz polymorph patent case dismiss march gilead file patent infringement action teva sdny relate orange bookliste patent atripla april gilead teva reach agreement principle settle lawsuit patent cover tenofovir disoproxil fumarate contain atripla truvada product baraclude august teva file anda manufacture market generic version baraclude company receive paragraph iv certification letter teva challenge orange bookliste patent baraclude patent patent cover entecavir molecule september company file patent infringement lawsuit district court district delaware delaware district court teva infringement february delaware district court rule company invalidated patent company appeal delaware district court decision decision expect firsthalf october teva anda generic version entecavir tentatively approve fda company prepare legal action event teva choose launch generic product prior resolution company appeal rapid significant negative impact net product sale baraclude begin early net product sale baraclude million baraclude south korea daewoong pharmaceutical co ltd hanmi pharmaceuticals co ltd initiate separate invalidity action korean intellectual property office kipo korean patent patent patent expire october korean equivalent patent composition matter patent invalidity action pende decision expect half outcome action unclear time risk decision invalidate patent encourage generic company launch generic version baraclude prior october net product sale baraclude south korea million plavixaustralia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex australian government intervene matter seek damage allege loss experience period injunction place possible time predict outcome australian government claim impact company plavixcanada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid june sanofi file defense impeachment action file suit apotex infringement patent trial complete june december federal court canada issue decision patent invalid july federal court appeal reverse federal court canada decision uphold validity patent case remand federal court canada consider damage owe company apotex infringement patent september apotex seek leave appeal decision federal court appeal supreme court canada february supreme court canada decide hear case general commercial litigation remain apotex matter relate plavix previously disclose november apotex file lawsuit new jersey superior court company sanofi seek payment million plus interest calculate rate month pay relate breakup march propose settlement agreement relate thethen pende plavix patent litigation apotex april new jersey superior court grant company crossmotion summary judgment motion deny apotexs motion summary judgment apotex appeal decision new jersey appellate division reverse grant summary judgment remand case superior court additional proceeding party agree resolve matter bind arbitration currently schedule march resolution matter expect material impact company january apotex file lawsuit florida state court broward county allege breach contract relate propose settlement agreement apotex relate pende plavix patent litigation trial hold march jury verdict deliver favor company apotex appeal decision pricing sale promotional practice litigation investigation abilify federal subpoena january company receive subpoena united states attorney office sdny request information relate thing sale marketing abilify possible time assess outcome matter potential impact company abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute company enter tolling agreement state possible time reasonably assess outcome investigation potential impact company abilify copay assistance litigation march company partner otsuka name codefendant putative class action lawsuit file union health welfare fund sdny plaintiff challenge legality abilify copay assistance program federal antitrust racketeer influence corrupt organization rico law seek damage company otsuka file motion dismiss complaint june court grant company motion dismiss claim allow plaintiff replead rico claim august plaintiffs move leave file amend complaint motion court grant claim allege tortious interference contract remain outstanding company possible time reasonably assess outcome litigation potential impact company time resolution matter expect material impact company awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende state court pennsylvania wisconsin begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company appeal decision pennsylvania supreme court oral argument take place qui tam litigation march company serve unseal qui tam complaint file sale representative california superior court county los angeles california department insurance elect intervene lawsuit complaint allege company pay kickbacks california providers pharmacy violation california insurance frauds prevention act cal in code possible time reasonably assess outcome lawsuit impact company product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california illinois new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court possible time reasonably assess outcome lawsuit potential impact company reglan company number defendant numerous lawsuit behalf approximately plaintiff include injury plaintiff claim personal injury allegedly sustain reglan brand generic drug metoclopramide product indicate gastroesophageal reflux certain gastrointestinal disorder claim spouse andor beneficiary company generic subsidiary apothecon inc distribute metoclopramide tablet manufacture party possible time reasonably assess outcome lawsuit resolution pende lawsuit expect material impact company hormone replacement therapy company number defendant masstort litigation plaintiff allege thing hormone therapy product include hormone therapy product manufacture company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer company agree resolve claim approximately plaintiff reach settlement principle resolve additional claim company remain defendant approximately actively pende lawsuit federal state court company hormone therapy product sell company january august resolution remain lawsuit expect material impact company byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf approximately plaintiff include injury plaintiff claim spouse andor beneficiary court company agree principle resolve claim majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego recently establish multidistrict litigation large contingent case pende coordinated proceed california superior court los angeles amylin lilly currently schedule trial singleplaintiff case february california superior court los angeles amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca possible reasonably predict outcome lawsuit claim proceed potential impact company bms august company announce discontinued development bms investigational compound test clinical trial treat hepatitis c virus infection emergence safety issue date company aware lawsuit file company plaintiff texas oklahoma virginia remove federal court alleging participate clinical trial bms suffer injury result thereof company settle vast majority know claim include file claim claim file state court remain outstanding resolution remain lawsuit potential future lawsuit expect material impact company environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate thirdpartie cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party new brunswick facilityenvironmental personal injury lawsuit lawsuit file company new jersey superior court behalf current resident new brunswick new jersey live live adjacent company new brunswick facility complaint allege personal injury result environmental contamination new brunswick facility historical operation site claim medical monitoring portion complaint assert claim allege property damage october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose october additional case file new jersey superior court remove company united states district court district new jersey accordingly excess case state federal court action discovery ongoing trial currently schedule commence state court august company intend defend vigorously litigation possible time reasonably assess outcome lawsuit potential impact company north brunswick township board education previously disclose october company contact counsel represent north brunswick nj board education boe site waste material er squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process party expect conduct fact expert discovery follow formal evidentiary hearing write argument hearing schedule commence march addition september township boe file suit party allege contribute waste material site company currently believe responsible additional amount interim payment total million transmit additional possible loss expect material proceeding sec germany investigation october sec inform company begin formal inquiry activity certain company german pharmaceutical subsidiary employee andor agent sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act fcpa company cooperate sec fcpa investigation march company receive subpoena sec subpoena issue connection investigation fcpa primarily relate sale marketing practice country company cooperate government investigation matter note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basic earning share dilute cash dividend declare common share cash cash equivalent marketable security total asset longterm debt equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss share basic earningsloss share dilute cash dividend declare common share cash cash equivalent marketable security total asset longterm debt equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset include current portion longterm debt follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell marketing selling administrativea research developmentb provision restructure pension settlement acquisition alliance relate item litigation chargesrecoverie upfront milestone licensing receipt incomeexpense increase pretax income income tax item increase net earning specify item marketing sell administrative process standardization implementation cost b specify item research development upfront milestone licensing payment second fourth dollar million quarter quarter quarter quarter year accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell stock compensation accelerate vest amylin award process standardization implementation cost marketing sell administrative stock compensation accelerate vest amylin award upfront milestone licensing payment iprd impairment research development impairment charge bms intangible asset provision restructure gain sale product line business asset pension settlement acquisition alliance relate item litigation chargesrecoverie upfront milestone licensing receipt outlicense intangible asset impairment loss debt repurchase incomeexpense increase pretax income income tax item specify tax benefita income taxis increasedecrease net earning specify tax benefit relate capital loss deduction report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule ae base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting december include amylin pharmaceuticals inc acquire assessment effectiveness internal control financial reporting change internal control financial reporting fourth quarter reasonably likely materially affect company internal control financial reporting item b information compensation management development committee board director approve new equity award guideline executive company begin equity award grant march award guideline express percentage salary fix dollar grade level committee approve new guideline respect name executive officer committee regularly schedule meeting february specific amount determined award grant march report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item b information require item respect executive officer registrant include ia reliance general instruction g instruction item b regulation sk item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item iv item